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ABSTRACT
Liquid Chromatography – Tandem Mass Spectrometry Techniques for
Drugs of Abuse as Applied to Bacterial and Forensic Toxicology
Stephanie Marie Martindale
The ability of bacterial species to transform complex chemical substances has
been well documented. Some of these species are native to the human gastrointestinal
tract and play an active role in the postmortem decomposition process. These species
have potential to cause biotransformations that affect compound-to-metabolite ratios
within the human body, especially after death. Postmortem changes such as these
have rarely been evaluated or taken into consideration but they have potential to supply
valuable information, especially concerning compound identification and confirmation.
The purpose of this research was to investigate the effects of Escherichia coli,
Bacteroides fragilis, and Clostridium perfringens on drugs of abuse, and to compare
these metabolites to those produced during normal human metabolism. To analyze and
quantify these effects, a novel liquid chromatography triple quadrupole tandem mass
spectrometry method was developed for diazepam, flunitrazepam, and metabolites in
Reinforced Clostridial Medium. Reinforced Clostridial Medium is a complex matrix
designed to provide the nutrients necessary to promote growth of bacterial species,
particularly Clostridia, other anaerobes, and specimens in clinical samples. To date,
similar methods of extraction, quantitation, and analysis of drugs of abuse in a nutrient
medium matrix have not been published.
After validation, the method was applied to assess the specific effects of human
gastrointestinal species on the targeted drugs of abuse. Experiments explored the
effects of individual bacterial species as well as a mixed culture on the benzodiazepine
compounds under anaerobic conditions. Diazepam and flunitrazepam were selected for
biotransformation studies because of their potential for abuse and prevalence in
analysis of both clinical and forensic specimens. Additionally, the human metabolites
for these compounds had been previously identified and reference standards were
commercially available.
A series of bacterial blanks were prepared in Reinforced Clostridial Medium and
incubated under experimental conditions. None of the bacterial specimens produced
interferences with the target analytes that satisfied peak shape, retention time, ion ratio,
and limit of quantitation requirements.
Analyte blanks were also prepared for analysis. Investigation of analyte blanks
and the mass balance for the reaction suggested that diazepam performed a partial,
unassisted degradation when incubated under experimental conditions. However,
neither nordiazepam, oxazepam, nor temazepam registered an increase between preto post-incubation concentrations. The degradation product was therefore unable to be
identified under current experimental conditions. In biotransformation studies,

diazepam showed a decrease in concentration between pre- and post-incubation for the
Escherichia coli and Bacteroides fragilis series of samples, while changes were minimal
for Clostridium perfringens and the mixed culture. Findings suggested that Escherichia
coli and Bacteroides fragilis were acting on diazepam; however there was no increase
in concentration for the human metabolites monitored. The discrepancy in mass
balance was potentially indicative of a unique bacterial metabolite not produced during
normal human metabolism.
Analysis of the flunitrazepam drug blanks likewise exhibited a decrease in
concentration. Unlike what was observed in the diazepam blank experiments however,
there was a corresponding increase in concentration for the 7-aminoflunitrazepam
metabolite in post-incubation samples. This accounted for some of the flunitrazepam
conversion. In biotransformation studies, samples incubated with Escherichia coli
demonstrated a greater decrease in flunitrazepam concentration than what was seen in
analyte blank samples, while Bacteroides fragilis, Clostridium perfringens, and the
mixed culture resulted in nearly complete conversion of flunitrazepam. Increased 7aminoflunitrazepam concentrations accounted for the majority of the conversion;
however data suggested production of a minor metabolite that was not monitored in the
current analysis.
These experiments served as a pilot study and proof of concept. Unlike previous
research, animal models were not required for experimental purposes, which eliminated
the ethical considerations and guidelines required for animal research. Frozen stock
cultures of bacterial samples provided a theoretically endless supply of specimens for
transformation studies, reducing cost. The streamlined methodology allowed for
quantities of experimental variations to be performed in unison, conserving time.
Extraction procedures, a narrow bore column, and low flow rate for instrumental
analysis minimized solvent consumption and hazardous waste production, making
analysis both cost-effective and environmentally friendly.
The presented experimental methodology serves as a template and can be
adapted and applied to a realm of possibilities including investigation of natural
products, biodegradation of agricultural and environmental contaminants, isolation and
repurpose of native bacterial enzymes, as well as further studies on pharmaceutical
compounds and drugs of abuse. An additional method was developed and validated for
quantitation of cocaine, fentanyl, and metabolites in Reinforced Clostridial Medium,
which will be applied in similar fashion. The applications can easily be expanded to
include alternative bacterial species as well. Ultimately, this methodology would be
ideal to study compounds that are too toxic or lethal for animal and human metabolic
investigations. This would be particularly useful in military explorations of exposure to
incapacitation and chemical warfare agents.
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Chapter 1: Introduction
1.1.0 Background Information
Compound detection, identification, confirmation, and quantitation are
cornerstone principles of analytical and forensic toxicology. These principles support
experimental investigations and applications to innovative areas of research and
development.
An exploration of previously published literature and research revealed that
bacteria were capable of metabolizing complex chemical substances such as food
additives and dyes, environmental contaminants, pharmaceutical compounds, and
drugs of abuse. Many of these studies resulted in novel applications toward agricultural
and environmental contaminant reduction or elimination, greater insight into the
effectiveness of pharmaceutical compounds, or innovative applications of isolated
bacterial enzymes.
Some of these same bacterial species are native to the human body and play an
active role in the postmortem decomposition process. After death, these species have
potential to cause biotransformations that affect the ratio of compound-to-metabolite
concentrations within the human body. To date, such postmortem changes have rarely
been evaluated or taken into consideration, but they have potential to supply valuable
information, especially concerning compound identification and confirmation.
The presented experimental methodology can be adapted and applied to a realm
of possibilities. The investigation of new natural products, further study of bacterial
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degradation capabilities for environmental contaminants such as pesticides, explosives,
and chemical warfare agents, and isolation and repurpose of native bacterial enzymes
for medical use or analyte detection purposes are just the beginning. Ultimately, this
methodology would be ideal to study compounds that are too toxic or lethal for animal
and human metabolic investigations. This would be particularly useful in defense and
military explorations involving exposure to incapacitation and chemical warfare agents,
especially in circumstances that result in casualties.

1.1.1 Agricultural Applications and Environmental Contaminants
Several studies have investigated the effects of bacterial species on compounds
found in food as well as environmental contaminants. Peppercorn and Goldman
determined that bacterial species isolated from human feces were capable of converting
caffeic acid, which is present in many foods and coffee, to dihydrocaffeic acid and
ethylcatechol.1 Metabolites were quantified using gas chromatography-mass
spectrometry (GC-MS). The authors discovered that individual bacterial species were
only able to achieve minimal caffeic acid conversion. However, they noted increased
metabolite production in feces for which they concluded conversion of caffeic acid likely
resulted from a joint effort amongst the multitude of bacterial species present.
The authors performed a similar set of experiments in which the metabolism of
caffeic acid was compared between germfree rats, gnobiotic rats, and conventional
rats.2 Germfree rats were born and maintained in the sterile environment at the
National Institutes of Health (NIH) Germfree Facility. Their diet was supplemented with
a 1% (w/w) addition of caffeic acid. Urinalysis revealed excretion of intact caffeic acid.
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Gnobiotic rats are those which are born in germfree conditions, but are
intentionally inoculated with a specific bacterial specimen or specimens. In this
instance, the gnobiotic rats were inoculated with a single strain of Bacteroides sp.,
Lactobacillus sp.1, Lactobacillus sp.2, or Streptococcus group N strain. The gnobiotic
rats inoculated with Streptococcus group N strain excreted caffeic acid as well as
dihydrocaffeic acid. Importantly, these rats were the only ones capable of transforming
caffeic acid, and the authors concluded that the Streptococcus group N strain had a
direct impact on this metabolic ability. Another set of gnobiotic rats was inoculated with
all four strains of bacteria. These rats excreted caffeic acid and dihydrocaffeic acid, as
well as two additional metabolites.
Conventional rats exhibited the greatest conversion of caffeic acid to several
metabolites. By comparing the metabolites produced by germfree, gnobiotic, and
conventional rats, the authors concluded that conversion of caffeic acid is affected by
the bacterial species present in the gastrointestinal (GI) tract of the host organism.
Islam et al. isolated a mixture of six bacterial genera including Citrobacter,
Clostridium, Enterococcus, Serratia, Stenotrophomonas, and Streptomyces from soil
samples collected in crop fields.3 This mixed culture converted deoxynivalenol (DON), a
contaminant of grains and cereals also known as “vomitoxin”, to de-epoxy DON.
Conversion occurred rapidly under aerobic conditions, and was monitored using liquid
chromatography-ultraviolet-mass spectrometry (LC-UV-MS). The authors proposed that
this method be applied to decontamination of tainted grain and corn crops. Methods
that use bacterial specimens and their degradation capabilities for decontamination and
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remediation purposes are advantageous because they do not rely on chemical
compounds and processes that could result in further environmental problems.
Bharagava and Chandra found that aerobic species Bacillus licheniformis
(DQ779010), Bacillus sp. (DQ779011), and Alcaligenes sp. (DQ779012) were capable
of biotransforming the compounds that cause distillery wastewater to appear dark brown
in color.4 Melanoidins are biopolymeric compounds produced by the Maillard reaction,
a reaction in which protein and sugar react when heated to produce brown coloration.
Caramel-colorants produced in the processing of sugarcane juice as well as distillation
of molasses also contributed to wastewater browning. Wastewater samples were
inoculated with a mixture of selected aerobic species, glucose, and peptone. Changes
in absorbance which correlated with changes in wastewater coloration were monitored
with a spectrophotometer.
The bacterial group was capable of converting approximately 70% of the color
compounds. An aliquot of the degraded wastewater sample was purified and analyzed
via liquid chromatography-tandem mass spectrometry (LC-MS/MS) to identify and
quantify metabolites produced. The authors suggested that their method could be an
effective means of environmental decontamination when applied to detoxification of
distillery wastewater.
Mohamed discovered a novel bacterial strain denoted Stenotrophomonas
maltophilia M1, which was isolated from water sources in Egypt contaminated with
pesticide residues.5 This strain was capable of degrading methomyl, a toxic pesticide
used to control insects and other pests, when glucose was present. Degradation
capabilities were analyzed by solid phase extraction-liquid chromatography-electrospray
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ionization-mass spectrometry (SPE-LC-ESI-MS). Mohamed suggested application of
M1 in bioremediation of the environment and water sources in areas contaminated with
methomyl.
Zhang et al. isolated a bacterial strain capable of efficient nicosulfuron
degradation. 6 Nicosulfuron is a sulfonylurea herbicide used to control weed growth in
crop fields and is also a source of groundwater pollution. Authors determined that
Serratia marcescens N80 was capable of utilizing nicosulfuron as a sole nitrogen
source, the effects for which were measured by liquid chromatography-mass
spectrometry (LC-MS). They proposed utilization of N80 in future bioremediation
attempts. Further analysis revealed that N80 was also capable of degrading several
other sulfonylurea herbicides as well.
Rafii et al. determined that Clostridium clostridiiforme, Clostridium leptum, and
Clostridium paraputrificum, amongst others species possessed a nitroreductase
capable of converting nitrated polycyclic aromatic hydrocarbons (nitro-PAHs) to various
aromatic amines.7 Nitro-PAHs are environmental contaminants found in diesel
emissions, spent motor oil, and urban air and pose human health risks. Bioconversion
decreased the mutagenic effects of the nitro-PAH compounds. The bacterial
nitroreductase was isolated and purified, and had potential to be an effective
environmental bioremediation agent for nitro-PAH compounds. Rafii and Cerniglia also
investigated a Clostridium perfringens azoreductase capable of cleaving azo dyes such
as Direct Blue.8,9
6-nitrochrysene is another nitro-PAH and known carcinogenic compound.
Manning et al. found that intestinal microflora were capable of converting 6-
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nitrochrysene to several metabolites.10 However, these products were also thought to
have negative toxicological capabilities, which hindered the effectiveness of
environmental remediation efforts.
Gallagher et al. discovered a Lysobacter-like bacterium capable of using 2,4,6trinitrotoluene (TNT) as both a carbon and nitrogen source under anaerobic
conditions.11 TNT is an explosive compound and persistent environmental contaminant.
The authors proposed usage of the Lysobacter-like bacterium in future TNT remediation
efforts. Similarly, experimental efforts by Nishino, Paoli, and Spain identified a single
strain of bacteria capable of degrading 2,4-dintrotoluene (2,4-DNT) as well as three
strains capable of degrading 2,6-dinitrotoluene (2,6-DNT).12 Both of these compounds
are components of TNT and are often seen as soil and water contaminants near former
TNT production sites. Combinations of the Lysobacter-like bacterium as well as the
species identified by Nishino, Paoli, and Spain may result in more efficient and complete
remediation efforts.11,12
Kuntze et al. identified Thauera chlorobenzoica as a specimen capable of
utilizing organohalides as sole carbon sources under aerobic as well as anaerobic
conditions.13 These halogenated aromatic compounds are ingredients in insecticides,
flame retardants, and lubricants and act as sources of negative human health effects as
well as environmental contaminants. T. chlorobenzoica degraded these compounds via
denitrification and have potential use in biodegradation efforts of organohalides.
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1.1.2 Pharmaceutical Compounds
In addition to the effects on environmental contaminants, several studies
demonstrated that some bacterial species are able to transform pharmaceutical
compounds. Peppercorn and Goldman performed studies comparing the effects of
germfree and conventional rats on salicylazosulfapyridine (SAS).14 SAS is a
pharmaceutical compound consisting of salicylate and sulfa drug components which act
as anti-bacterial and anti-inflammatory agents, respectively. It is often used in the
treatment of ulcerative colitis. Conventional rats dosed with SAS excreted urine and
feces samples containing the SAS metabolites 5-aminosalicylate (5AS) and
sulfapyridine (SP).
The germfree rat did not originally produce these metabolites. However, once
removed from the sterile environment, the rat gained the ability to reduce the azo bonds
of SAS and produced 5AS and SP. This study demonstrated that GI bacteria are
capable of reducing pharmaceutical compounds, which may provide an explanation for
differences in human responses to pharmaceutical drugs as well as treatment
effectiveness.
Metonidazole is a pharmaceutical compound used in the treatment of
trichomonal vaginitis and anaerobic bacterial infections. Koch and Goldman compared
results of germfree and conventional rats, and determined that GI bacteria were
responsible for the transformation of metonidazole to N-(2-hydroxyethyl)-oxamic acid.15
This metabolite was seen in conventional rats but not in their germ-free counterparts.
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1.1.3 Drugs of Abuse
A few studies have described the ability of some bacterial species to transform
drugs of abuse. Robertson and Drummer studied the effects of eight GI species
including Bacteroides fragilis, Bacillus spp., Clostridium perfringens, Escherichia coli,
Proteus miribalis, Staphylococcus aureus, Staphylococcus epidermidis, and
Streptococcus faecalis on clonazepam, flunitrazepam, and nitrazepam in blood.16
Samples were analyzed via high performance liquid chromatography with ultraviolet
detector (HPLC-UV).17 All three drugs were converted to their respective 7-amino
metabolites though the rate of metabolism varied between species. 16 Effects of pH and
temperature were examined as well. Changes in pH affected the rate of metabolism for
most species, but there was no discernible trend. However, as temperature increased
from 4°C to 22°C to 37°C, all eight GI species demonstrated greater efficiency in
metabolism.
Bressler et al. isolated a Rhodococcus sp. strain designated as MB1 from soil
near Erythroxylum coca, the plant from which cocaine is produced.18 Authors
determined that MB1 was capable of utilizing cocaine as a sole source of both carbon
and nitrogen. Cocaine was hydrolyzed to form ecgonine methyl ester, a metabolite
commonly seen in human metabolic studies, as well as benzoic acid. The authors
extracted the Rhodococcus sp. cocaine esterase and proposed to utilize it in the design
of a sensor for cocaine detection.
A strain of Pseudomonas maltophilia (MB11L) was also capable of utilizing
cocaine as a sole carbon source.19 Britt, Bruce, and Lowe isolated this species from
industrial waste and performed subsequent analysis. Like the Rhodococcus sp.,
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MB11L converted cocaine to ecgonine methyl ester and benzoic acid. Analyses were
performed using HPLC-UV and gas chromatography with a flame ionization detector
(GC-FID).
Brim et al. developed a mutated Rhodococcus cocaine esterase known as DMCocE.20, 21 This enzyme hydrolyzed cocaine as well as metabolites norcocaine and
cocaethylene, but had no effect on benzoylecgonine. Metabolites were quantified using
LC-MS/MS.21 The authors aimed to apply the enzyme to the treatment of cocaine
addiction as well as in treatment of cocaine toxicity as a result of overdose.20,21
Labroo et al. compared the extent and rate of fentanyl metabolism by human liver
microsomes and duodenal microorganisms.22 Samples were quantified via GC-MS.
Both systems converted fentanyl to dealkylated metabolite norfentanyl; however the
liver performed the conversion twice as quickly. Cytochrome P450 3A4 was identified
as the predominant enzyme responsible for the conversion of fentanyl to norfentanyl in
both the liver and duodenum.
Cameron et al. isolated a Rhodococcus sp. (H1) from garden soil.23 H1 was
capable of utilizing heroin as a sole carbon source, hydrolyzing it into morphine.
Authors planned to purify the heroine esterase and combine it with a previously
discovered morphine dehydrogenase isolated from Pseudomonas putida (M10) in an
effort to create a biosensor for heroin detection.

1.2.0 Purpose
The purpose of this research was to investigate the effects of several bacterial
species on drugs of abuse, and to compare these metabolites to those produced during
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normal human metabolism. To analyze and quantify these effects, a novel liquid
chromatography-tandem mass spectrometry (LC-MS/MS) method was developed for
analytes of interest as well as the corresponding human metabolites in Reinforced
Clostridial Medium (RCM). The method was used to investigate and analyze the
specific effects of human GI species on the targeted drugs of abuse compounds. At the
onset of this research, similar methods of extraction and quantitation of drugs of abuse
in a nutrient medium matrix and application toward analysis of biotransformation studies
had not been published.

1.3.0 Application
Comparing the metabolites produced by bacteria to those of human metabolism
was considered a particularly interesting area of exploration. This research focused on
the effects of GI bacteria, specifically Escherichia coli, Bacteroides fragilis, and
Clostridium perfringens on common drugs of abuse. These bacteria were chosen
because they are prevalent in the GI tract and have demonstrated biotransformation
capabilities which are summarized in sections 1.1.1 – 1.1.3. Preparation and growth of
these species are discussed in Chapter 2.
Diazepam (DZ), flunitrazepam (FLU), cocaine (COC), and fentanyl (FENT) were
chosen as the initial analytes of interest. They are all classified as drugs of abuse by
the United States Drug Enforcement Agency (DEA), Schedule II-Schedule IV, and are
therefore of forensic importance.24 Drug use and overdose are common occurrences,
and drug selection was based upon compounds for which human metabolism studies
have been well documented and commercial standards were readily available. Table 1
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depicts the analytes of interest as well as the corresponding structure, formula, and
molecular weight.
Table 1 – Analytes of Interest
Analyte

Structure

Empirical Formula

Molecular Weight (g/mol)

DZ

C16H13ClN2O

284.7

FLU

C16H12FN3O3

313.3

COC

C17H21NO4

303.4

FENT

C22H28N2O

336.5
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1.4.0 Analysis
Analytes were extracted from RCM using solid phase extraction (SPE). RCM is
a complex matrix designed to provide the nutrients necessary to promote growth of
bacterial species, particularly Clostridia, other anaerobes, and specimens encountered
in clinical samples. RCM components are detailed in Table 2. The SPE methods
focused on reduction of matrix interferences, particularly the salts and polar
components of the media, which could inhibit effectiveness instrumental analysis.
Table 2 – Reinforced Clostridial Medium Components
Components










Conditions

10.0 g Beef Extract
10.0 g Peptone
3.0 g Yeast Extract
5.0 g Dextrose
5.0 g NaCl
3.0 g NaC2H3O2
1.0 g Soluble Starch
0.5 g Cysteine HCl
15.0 g agar for RCM agar

Adjust to 1.0 L
Final pH = 6.8 ± 0.2
Autoclave @121°C
for 15 minutes.

LC-MS/MS was chosen as the analytical technique for several reasons. The
compounds of interest exhibited structural similarities and displayed similar
fragmentation patterns under common analytical processes. High performance liquid
chromatography (HPLC) allowed for selection of both solid (column) and mobile phases
(buffers) as well as buffer composition, type of elution, flow rate, and column
temperature to enhance separation and selectivity of the closely related and structurally
similar analytes. Triple quadrupole (QQQ) tandem mass spectrometry (MS/MS) was
12

chosen for sensitivity and additional selectivity with mass analysis performed in multiple
reaction mode (MRM). Analyte-specific ion transitions were quantified in narrow
windows corresponding to retention time.

1.5.0 Method Validation
Compound detection, identification, confirmation, and quantitation are
cornerstone principles of analytical and forensic toxicology. These principles support
development of experimental investigations and applications for innovative areas of
research and development. To perform analysis with reliability and certainty, a method
must be validated. There are many published guidelines available that discuss
validation requirements; however, there is a degree of subjectivity to be evaluated by
the analyst. Methods development and validation were discussed in Chapter 3 and
Chapter 5 of this research.
For method validation, the intended use of the method should dictate the design
of the validation plan as well as parameter selection. Validation parameters should be
examined under the same analytical conditions and using the same SPE and
instrumental techniques as the final method. Finally, the parameter definitions and
validation should be reported so that experiments and analysis could be reasonably
reproduced by an alternative analyst or laboratory.
In this research, validation definitions and practices were based upon the
International Conference on Harmonisation (ICH) guidelines for linearity, specificity,
accuracy, precision, repeatability, detection limit, quantitation limit, range, and
robustness.25 The Scientific Working Group for Forensic Toxicology (SWGTOX)
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Standard Practices for Method Validation in Forensic Toxicology26 and the Guidance for
Industry: Bioanalytical Method Validation27 produced by the U.S. Department of Health
and Human Services (DHHS), Food and Drug Administration (FDA), Center for Drug
Evaluation and Research (CDER), and Center for Veterinary Medicine (CVM) were also
used as references.
1.5.1 Linearity
Linearity was defined as the method’s ability to achieve responses that are
directly proportional to analyte concentration within a given range.

27

A calibration

model was used to address the linearity for each analyte of interest. Most guidelines
required four to six points in creation of the calibration curve.26, 27 For purposes of this
research, calibration models consisted of a 10-point calibration set prepared and
extracted from RCM. The 10-point calibration was chosen because it allowed for
adjustment to the model for each analyte based upon the limit of detection and range,
while maintaining the requirement of six calibration points. The curve was constructed
as a linear model ignoring the origin, and with 1/x weighting. The correlation coefficient
(R2) was used to assess the linearity of each analyte in the method. The calibration
model was one of the most important validation parameters assessed. All subsequent
analysis and quantitation values are all based upon the relationship established in the
calibration model.
1.5.2 Carryover Effects
Carryover analysis was conducted for a minimum of three concentration levels
including the highest calibration point.26 Two points at concentrations higher than those
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included in the calibration model were also investigated. An extracted blank was
injected after each sample and carryover effects were determined by analysis of the
blank injections.
1.5.3 Specificity
The specificity of a method was defined as the ability to evaluate the analyte of
interest in the presence of matrix components or impurities.
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Specificity was

determined by conducting interference studies as well as assessing ionization
suppression/enhancement, matrix effects, recovery, and process efficiency. 26
1.5.3.1

Interference Studies

Ten samples of RCM matrix were prepared, pooled, and autoclaved at 121°C for
15 minutes. Blank samples were extracted and then analyzed to assess possible
interferences between matrix components and the analytes of interest. Possible
interferences were identified based upon retention time, peak shape, and ion ratios of
the target analytes. Ion ratios were calculated as a ratio of response between
qualitative ion: quantitative ion. Blank matrix was also spiked with deuterated standards
to address possible interferences arising from similar fragmentation patterns of target
analyte and corresponding deuterated standard. 26
1.5.3.2

Ionization Suppression/Enhancement and Recovery

Ionization suppression/enhancement studies were combined with matrix effect
(ME), recovery (RE), and process efficiency (PE) studies. Analysis was based on
methods published by SWGTOX26 and Matuszewski.28 Samples were prepared in 3
sets. Set A consisted of neat samples prepared in buffer. Set B consisted of post15

extraction samples for which 1 mL of blank matrix was extracted and dried and then
spiked with the appropriate amounts of working standard, internal standard, and
reconstitution buffer to achieve the desired concentration. In Set C, matrix samples
were spiked with analytes and internal standards and then extracted, dried, and
reconstituted in 1 mL of buffer. Samples were analyzed in triplicate. The following
equations were used to calculate the percentage ME as determined by ionization
suppression or enhancement (Equation 1), RE (Equation 2), PE (Equation 3).
Equation 1 – Matrix Effect (%)

Equation 2 – Recovery (%)

Equation 3 – Process Efficiency (%)

1.5.4 Accuracy
Accuracy was defined as the degree of agreement between the experimental and
theoretical values.27 Accuracy was calculated using Equation 4.26 The acceptable
accuracy range was established at ±20% (80-120%) of the theoretical concentration
value.
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Equation 4 – Accuracy (%)

1.5.5 Bias
The bias of the method was also determined by the agreement between the
experimental and theoretical values.26 However, bias measures the agreement
between all the samples at a given concentration level. The % bias was calculated
using Equation 5 where the grand mean of [EXP] (experimental concentration)
represents the average of the entire concentration level and [THEO] is equal to the
theoretical or known value for that concentration level. The acceptable range for bias
was established at ±20% of the theoretical concentration value.
Equation 5 – Bias (%)

1.5.6 Precision
Precision was defined as the agreement between replicate analyses of the same
sample. 27 The SWGTOX guidelines referred to this as within-run precision.26
Data used in bias calculations were also used in precision calculations. The within-run
precision was determined by analyzing the triplicate runs for each sample as seen in
Equation 6 where [Run] represents the mean of the triplicate runs and σR represents
the standard deviation of the mean between the triplicate runs. The within-run precision
for each concentration level was considered to be the highest calculated within-run %
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CV for each concentration set. The acceptable range for within-run precision was
established at ±20% of the theoretical concentration value.
Equation 6 – Within-Run Precision (%CV)

1.5.7 Repeatability
Repeatability was defined as a measure of agreement between samples in a
short period of time under the same operating conditions. 27 The SWGTOX guidelines
refer to this as between-run precision.26 Between-run precision was determined by
analyzing the 5 runs at the same concentration level. Between-run precision was
calculated using Equation 7 where [Level] represents the grand mean of the
concentration level and σL represents the standard deviation of the grand mean of all
the runs at each concentration level. The between-run precision for the method was
considered to be highest calculated between-run CV for each concentration level. The
acceptable range for between-run precision was established at ±20% of the theoretical
concentration value.
Equation 7 – Between-Run Precision (%CV)

1.5.8 Detection Limit
Detection limit was defined as the concentration at which an analyte can be
detected, but is not necessarily able to be quantified. 27 This was also referred to as the
limit of detection (LOD). SWGTOX requirements for LOD were more specific.26 The
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LOD was determined to be the lowest concentration for which the analyte demonstrates
acceptable peak shape, retention time, and ion ratios as well as a signal response equal
to at least three times greater than the background noise response (S/N ≥ 3). This was
determined for each analyte.
1.5.9 Quantitation Limit
The quantitation limit was defined as the lowest concentration for which an
analyte can be quantified with acceptable accuracy and precision.

27

SWGTOX

requirements for limit of quantitation (LOQ) included LOD requirements of peak shape,
retention time, and ion ratios as well as acceptable accuracy and precision. 26 This was
also calculated for each analyte, the value for which served as the concentration on the
calibration model.
1.5.10 Range
The range of an analyte was defined as the values between the LOQ and the
highest calibration value over which a linear response was maintained.27 All method
calibration curves we prepared according to these guidelines.
1.5.11 Dilution Integrity
Dilution integrity was an important feature of method validation, especially when
applied sample concentrations exceeded the calibration range of the analyte of
interest.26 To determine dilution integrity, bias and precision studies were recalculated
for the diluted samples. Dilution integrity was analyzed at 1:2, 1:5, and 1:10 ratios. Five
samples per concentration level were prepared, extracted, and analyzed in triplicate.
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1.5.12 Stability
1.5.12.1 Freeze-Thaw Stability
Freeze-thaw (FT) stability and processed sample stability were both assessed as
part of the method validation.26 For freeze-thaw analysis, three samples per
concentration were prepared in media and frozen for 24 hours. All of the samples were
thawed at room temperature. One vial from each concentration level was extracted and
analyzed (FT1) while the other two were frozen for an additional 24 hours. The cycle
was repeated for FT2 and FT3. This type of analyte stability was important for samples
that could not be analyzed immediately and were frozen for preservation.
1.5.12.2 Processed Sample Stability
The stability of processed samples was studied to address possible effects of
large sample batches or instrument malfunctions that could prevent samples from being
analyzed immediately.26 Stability studies were conducted at two concentrations, high
and low. Two samples were prepared in RCM at each concentration, extracted,
reconstituted, and analyzed in triplicate over 48-60 hours.
1.5.13 Robustness
Robustness of a method is defined as the ability to remain unaffected as slight
variations are made to method parameters.25,26 Robustness of the method was
determined by slight changes in the buffer composition and column temperature. In
addition to buffer composition and column temperature, an alternate analyst prepared
samples for analysis.
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Chapter 2: Optimization of Bacterial Growth and Preparation
2.1.0 Introduction
Anaerobic bacteria endogenous to the human body are active in the postmortem
decomposition process. To study the effects of these species on the selected drugs of
abuse, bacterial methods were developed and optimized. A nutrient medium,
environmental and growth conditions, and methods of cellular lysis were selected and
optimized. A frozen stock culture was prepared for future experiments and a serial
dilution and plate count method was used to estimate the number of viable bacteria.

2.2.0 Background
Cellular metabolism is estimated to continue for approximately 4-10 minutes
postmortem.29 During this interval, carbon dioxide (CO2) begins to accumulate which
lowers pH. This continues until the acidity reaches concentrations capable of rupturing
cellular membranes. Lysing of these membranes causes the release of digestive
enzymes, and marks the beginning of the decomposition process.29-31
The decomposition process is typically broken down into four stages: autolysis,
putrefaction, decay, and diagenesis.30,31 In the autolysis or self-digestion phase, cellular
enzymes begin to dissolve the remaining cellular structures from within. These
chemical changes within the cell along with decreasing oxygen and increasing carbon
dioxide cause waste to accumulate and poison the cell. Resulting fluids from these
processes lead to putrefaction. Putrefaction is marked by catabolism of the soft tissue

21

by endogenous bacteria and microbes, especially those native to the GI tract. The
catabolic processes result in production of various gases such as ammonia (NH3),
methane (CH4), carbon dioxide (CO2), and hydrogen sulfide (H2S) as well as a variety of
liquid byproducts. After the soft tissues have been broken down, the body enters decay
in which remaining protein and fats are decomposed. The final stage of decomposition
is diagenesis and is marked by the degradation of bones. Anaerobic bacteria and
microbes endogenous to the human body are active in the postmortem decomposition
process, especially during the putrefaction and decaying phases.30,31
Indigenous microflora colonize much of the human body both on the surface and
internally. Though the intestinal tract is sterile at birth, a “mature” microfloral
environment is established within 3-4 weeks of life. The numbers and types of bacteria
differ between regions of the body based upon pH conditions and the oxygen
requirements of the microbes themselves.32,33
Table 3 lists approximations of the number of viable bacteria in each section of
the GI tract per gram of sample taken.32-34 While a total bacterial count includes both
living and dead organisms, the viable bacteria count estimates the number of bacteria
present that are living and able to both grow and divide; thus, capable of metabolic
activity.32,33
Table 3 – pH and Viable Microbial Populations in the Human Digestive Tract

Viable Bacteria/Gram
pH

Stomach
0 - 103
3.0
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Jejunum
0 - 104
6.0-7.0

Ileum
105 - 108
7.5

Colon
1010 - 1012
6.8-7.3

This research focuses on the lower GI tract, particularly the ileum and colon. In
these sections, the oxygen concentration is limited, which promotes the largest
populations of facultative anaerobic and anaerobic species. Table 4 contains
information pertaining to the most abundant facultative anaerobic and obligate
anaerobic bacteria endogenous to the human intestinal tract. It also includes basic
information pertaining to Gram-stain, morphology, and oxygen requirements for each
species. 32,35
Table 4 – Prevalent Bacteria in the Lower GI Tract
Bacteria
Bacteroides sp.
Clostridium sp.
Enterococcus faecalis
Escherichia coli
Proteus sp.
Staphylococcus aureus
Staphylococcus epidermidis
Streptococcus mitis
Streptococcus pyogenes
Enterobacteriacea
Lactobacillus sp.

Gram
+
+
+
+
+
+

Morphology
Bacillus
Bacillus
Coccus
Bacillus
Bacillus
Coccus
Coccus
Coccus
Coccus
Bacillus
Bacillus

O2 Requirements
Obligate Anaerobe
Obligate Anaerobe
Facultative Anaerobe
Facultative Anaerobe
Facultative Anaerobe
Facultative Anaerobe
Facultative Anaerobe
Facultative Anaerobe
Facultative Anaerobe
Microaerophile/Anaerobe
Microaerophile/Anaerobe

The Gram-stain is commonly used as the starting point in classification and
identification of bacterial samples.34-36 It is a differential staining technique, which
distinguishes between Gram-positive and Gram-negative specimens based upon
structural differences in the cell walls. Gram-positive bacteria have more disaccharides
and amino acids which form a thicker peptidoglycan layer and stain purple, while Gramnegative bacteria have a lipopolysaccharide layer which consists of lipids and
polysaccharides that stains pink. The Gram staining procedure is also useful for
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determining the morphology or shape of a specimen as well. The morphology of a
bacterium is used in further classification and identification. There are three categories:
coccus specimens who are spherical, bacillus specimens who are rod-shaped, and
spiral specimens.
Bacteria are classified into five categories based upon requirement for and
tolerance of atmospheric oxygen.34-36 Aerobic species are those which require
abundant oxygen for metabolic processes and growth, while microaerophilic species
require only a finite amount of oxygen and can be metabolically hindered or even killed
by excessive amounts. Facultative anaerobes prefer oxygenated environments for
aerobic respiration, but are also capable of cellular respiration and fermentation under
limited oxygen or anaerobic conditions. Aerotolerant anaerobic species are
fermentative and prefer oxygen-poor environments, but can tolerate the presence of
oxygen, while obligate anaerobic species require the absence of oxygen.34,36 A
depiction of oxygen requirements can be seen in Figure 1.34 Though bacteria from all
five categories can be found in the human body, the oxygen content of the GI region is
strictly limited or absent. Therefore, the bacteria of interest for the purposes of this
research are facultative or obligate anaerobes.
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Figure 1 – Determination of Oxygen Requirements

Aerobe
Microaerophile
Facultative Anaerobe
Aerotolerant
Obligate Anaerobe

Three of the bacterial species discussed in Table 4 were chosen for analysis and
include Escherichia coli (E. coli), Bacteroides fragilis (B. fragilis), and Clostridium
perfringens (C. perfringens). E. coli was chosen because it is commonly used in
microbial research. It is also a facultative anaerobic species highly concentrated in the
human gastrointestinal tract. Since the oxygen concentration is severely limited in the
ileum and colon, the two obligate anaerobic species B. fragilis and C. perfringens were
also chosen for observation in this research. Effects of these bacterial specimens on
the targeted drugs of abuse were investigated. Results are discussed in Chapter 4.
Postmortem, the populations of GI microflora are capable of otherwise inhibited
transmigration.37 The body’s protective mechanisms both physical (membranes) and
chemical (pH conditions) are compromised. Bacteria are therefore no longer limited to
their native habitats within the body, and are allowed access to areas that were
previously protected, including the bloodstream and contents of the stomach to name a
few.
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Melvin et al. conducted a series of experiments using a combination of culturing
techniques and scanning electron microscopy (SEM) to evaluate bacterial
transmigration.37 In these experiments, a Carworth Farms No. 1 (CF-1) mouse was
decapitated and the small intestine removed. The intestine was divided into three
sections. The first section, the “control”, was immediately placed in a cold solution of
2.5% buffered glutaraldehyde, and was used to assess tissue and environmental
conditions of the sample immediately postmortem. The middle section of the small
intestine was cauterized and stored in solutions of phosphate-buffered saline. The third
section was used to evaluate the types of endogenous microbial organisms present via
culturing techniques.
The preparations were incubated at 4°C, 25°C, and 37°C to ascertain the effect
of temperature on the rate of bacterial transmigration. Samples of the gut were taken at
intervals over a 72 hour period for each temperature study. Fixed tissue samples of the
gut were dehydrated in ethanol, dried, coated with gold, and examined with the SEM.
Aliquots of the saline solution containing the middle section of the small intestine were
taken at the same intervals for culturing.
SEM analysis revealed that microbes migrated to the surface of the gut tissue
within 2-3 hours at 37°C. Appearances were delayed to 5-6 hours when incubated at
25°C and 72 hours at 4°C. Culture analysis demonstrated that rate of migration also
depended upon the type microbial organism. For example, Staphylococcus species
were some of the first organisms cultured, regardless of temperature. The authors
attributed this to the high concentrations of collagenase and protease enzymes inherent
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to these species. Fungi, coliforms, and facultative anaerobic species were cultured in
later samples.
Table 5 was adapted from the results of Melvin et al.37 This study indicated that
many of the bacteria endogenous to the human intestine would be capable of
transmigration within 72 hours postmortem, regardless of temperature.
Table 5 – Microbial Transmigration Analysis: Time of Appearance
Temperature
4°C
25°C
37°C

Staphylococcus Species Coliforms/Fungi
66-88 Hours
68-72 Hours
5-6 Hours
8-10 Hours
2-3 Hours
4-5 Hours

Coliforms/Anaerobes
>72 Hours
12-16 Hours
6-8 Hours

2.3.0 Bacterial Selection
E. coli, B. fragilis, and C. perfringens were all classified as Biosafety Level 2
(BSL-2) organisms.38 BSL-2 specimens are those which act as a potentially moderate
threat to both the environment as well as personnel.39 Each of the organisms was
specifically chosen due to human origin, and were ordered from the American Type
Culture Collection (ATCC).38 The specific characteristics for E. coli 33985 are listed in
Table 6.
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2.3.1 Bacterial Characteristics
Table 6 – Characteristics of E. coli
ATCC Number
Organism
Designation
Isolation
Biosafety Level
Antigenic Properties

33985TM
Escherichia coli (Migula) Castellani and Chalmers
B7
Feces (Human)
BSL-2
Serotype O86a:K61

E. coli is a Gram-negative, rod shaped bacterium.38 It can be seen in various
arrangements including singles, pairs, and short chains. Size ranges between 0.5 μm in
width and 1.0-3.0 μm in length. A Gram stain of E.coli can be seen in Figure 2.
Colonies are opaque gray/white while broth specimens are generally turbid with
sediment. E. coli can act as an anaerobic microbe as well as a facultative anaerobe.
Possible growth temperatures range from 10-45°C, optimally between 30-37°C.
Figure 2 – Gram Stain of E. coli
Reproduced with permission by Gary E. Kaiser
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B. fragilis is a Gram-negative, rod shaped bacterium commonly seen in singles or
pairs.38 Size ranges between 0.5μm in width and 1.0-3.0μm in length. Colonies tend to
be small, gray, and irregular, and broth specimens are turbid. B. fragilis is an anaerobic
species with optimal growth at 37°C. Table 7 shows characteristic of the B. fragilis
specimen selected from the ATCC.38
Table 7 – Characteristics of B. fragilis
ATCC Number
Organism
Designation
Isolation
Biosafety Level

29771TM
Bacteroides fragilis (Veillon and Zuber) Castellani and Chalmers
2044; [CDC 1261; M-488]
Blood
BSL-2

C. perfringens is a Gram-positive, rod shaped bacterium commonly seen in
singles or pairs.38 Size ranges between 1.0-1.5 μm in width and 4.0-8.0 μm in length.
Colonies are circular and slightly raised with an opaque center. Broth specimens are
usually turbid with sediment. C. perfringens is an encapsulated and spore forming
anaerobic species. Growth is possible up to 50°C with optimal growth between 3537°C. Table 8 shows the C. perfringens specimen chosen from the ATCC catalog.38
Table 8 – Characteristics of C. perfringens
ATCC Number
Organism
Designation
Isolation
Biosafety Level

19574TM
Clostridium perfringens (Veillon and Zuber) Hauduroy et al.
43F4
Bile (Human)
BSL-2
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2.4.0 Media Selection
Several types of nutrient media were evaluated. Components and conditions for
M9 Medium (M9M) and tryptic soy medium (TS) were described in Table 9.38,40
Components and conditions of RCM were previously discussed in Table 2. Information
about M9 salts, modified Wolin salts, and M9M were obtained from Melissa Dixon at
Edgewood Chemical Biological Center.41
Table 9 – Preparation of Nutrient Media
Medium
M9 Salts

Modified Wolin Salts

M9M

TS



























Components
64.0 g Na2HPO4•7H2O
15.0 g KH2PO4
2.5 g NaCl
5.0 g NH4Cl DI H2O
3.0 g Nitrilotriacetic Acid
6.0 g MgSO4•7H2O
1.0 g NaCl
1.0 g MnSO4•H2O
0.50 g FeSO4•7H2O
0.10 g CaCl2•2H2O
0.10 g CoCl2•6H2O
0.10 g ZnSO4•7H2O
0.020 g H3BO3
0.010 g NaMoO •2H2O
0.010 g CuSO4
200.0 mL M9 Salts
2.0 mL 1M MgSO4
0.10 mL 1M CaCl2
10.0 mL Modified Wolin Salts
17.0 g Tryptone
3.0 g Soytone
2.5 g Glucose
5.0 g NaCl
2.5 g K2HPO4
15.0 g Agar for TS Agar
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Conditions
Adjust to 1.0 L

Adjust to 1.0 L

Adjust to 1.0 L

Adjust to 1.0 L
Autoclave @121°C
for 15 minutes

M9M was prepared and then filtered to sterilize. The broth of RCM and TS were
prepared and autoclaved for sterilization. A tube containing 10 mL of broth was
inoculated with either E. coli, B. fragilis, or C. perfringens. This was performed for all
broth and bacteria combinations. The tubes were incubated for 24 hours at 37°C under
anaerobic conditions. None of the bacterial species demonstrated growth in M9M. This
was attributed to the fact that M9M is a limited nutrient medium. Bacteria require
sources of carbon and nitrogen for growth, which are absent in M9M. However, this
medium would be ideal for sole source studies.
E. coli demonstrated growth in TSB as evidenced by the cloudy nature of the
broth post-incubation. However, the tubes inoculated with B. fragilis and C. perfringens
remained the clear yellowish-brown of freshly sterilized TSB. This indicated bacterial
growth for these species was not supported by TSB, making it a poor choice for
experimental medium. RCM supported and promoted growth of all three species and
was therefore selected as the matrix for all of the experimental procedures.

2.5.0 Certificates and Training
Specific certifications and training were required for those handling or working
with BSL-2 agents as well as for the laboratory itself.39 WVU required approval and
clearance from the Director of Biological Safety for research involving biohazards. WVU
also required biosafety training through the Collaborative Institutional Training Initiative
(CITI) program, which offered a Biosafety and Biosecurity (BSS) course.42 In addition,
The Centers for Disease Control and Prevention (CDC) also recommended a
Laboratory Biosafety Training online course.43
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Edgewood Chemical Biological Center (ECBC), a facility under the United States
Army Research, Development and Engineering Command (RDECOM) required
completion of the Effective Engineering Controls for Biological and Chemical Operations
training set as well as the ECBC Visitor Risk Assessment for Chemical and Biological
Non-Surety Laboratories. The training requirements were fulfilled prior to
commencement of the dissertation research.
The experimental research was performed in the research labs of Dr. Suzanne
Bell at West Virginia University as well as the facilities of Edgewood Chemical and
Biological Center on the Aberdeen Proving Ground under Dr. Frederic Berg, Dr. Steve
Harvey, and Melissa Dixon. All of these facilities obtained the necessary permissions
for the BSL-2 human specimen and bacterial work.

2.6.0 Anaerobic Conditions
Growth conditions and requirements for the anaerobes are specific. Therefore,
methods were developed to ensure optimal growth for each species. Coy Laboratory
Products, Inc. specializes in various types of anaerobic chambers.44 The Vinyl
Anaerobic Chamber is specifically designed to meet the needs for anaerobic
microbiology research and can be seen in Figure 3.
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Figure 3 – Coy Laboratory Products, Inc. Type A Vinyl Anaerobic Chamber
Reproduced with permission from Brian Coy of Coy Laboratory Products, Inc.

All models are equipped with an airlock system, gas regulator, catalyst fan
boxes, 2 stak-paks with catalyst, a gas leak detector, and a plug strip for electronics
(Coy Laboratory Products). The Type A Chamber with automatic airlock and an
incubator was chosen for this set of research experiments. A schematic of the chamber
setup is depicted in Figure 4.
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Figure 4 – Schematic of the Type A Vinyl Anaerobic Chamber
77”

36”
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Glove Ports

Airlock

N2

Coy’s airlock and chamber systems require a combination of two gases. A
background gas, N2, was used to purge most of the oxygen out of the system through
the vacuum pump and to inflate the chamber. The second gas was a mixture of 95% N2
and 5% of H2. The H2 combined with O2 molecules within the chamber to form H2O
molecules. The stat-pak in each catalyst fan box contained a palladium catalyst which
facilitated this reaction, and were switched out every 24 hours and dried in a laboratory
oven to remove water and ensure optimal performance.
The vinyl chamber offered several advantages over the aluminum and polymer
versions. The vinyl chamber required less combination gas consumption and anaerobic
conditions were easier to maintain because of the ability of the walls to expand and
contract. In addition, vinyl chambers have the lowest cost-per-life cycle of all the
models.
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2.7.0 Frozen Stock Culture (3 Days)
Prior to use, the ATCC cultures were stored at manufacturer recommended
temperature, -80°C. To ensure an adequate supply of bacteria for experimental
procedures, a set of 10 stock cultures was prepared for each of the three species. On
day one, the plastic vial containing the lyophilized bacterial sample was removed from
the protective packaging and placed in the anaerobic chamber. A 1mL aliquot of sterile
water was added to the vial. Contents were vortexed and then transferred to a sterile
BD Falcon™ tube (15 mL) containing 10 mL of RCM and incubated at 37°C. This was
repeated for all three bacterial specimens. After 48 hours of incubation, tubes were
removed from the incubator and examined for growth. All three samples produced
turbid cultures with a layer of bubbles as well as what appeared to be a gelatinous
mixture that was present in all of the tubes. This was identified as a small amount of
agar, a component of RCM, which provided support to the anaerobic cultures. It
solidified to a slight extent during incubation. After the samples were vortexed, the
gelatinous portion mixed back in with the RCM broth.
A 500 uL aliquot of 15% sterile glycerol in water was transferred into 10 small
Eppendorf tubes per bacterial species. The RCM culture tubes were removed from the
incubator and vortexed for 30 seconds. A 500 uL aliquot of this solution was transferred
into each of the glycerol-water tubes. The tubes were then sealed, gently vortexed to
mix, and nine of them stored at -80°C for future use.
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2.8.0 Plate Count Procedure (5 Days)
There are many different methods used in the enumeration of bacteria or other
microorganisms in a sample. Direct microscope counts, electronic cell counters, and
spectrophotometric analysis are all commonly used.34, 36 However, while these methods
are capable of approximating the number of organisms within a sample, they offer one
major disadvantage. They are programmed to count the number of living, viable cells
as well as any dead cells within the sample.36 For this set of experiments, it was
important to only approximate the number of viable cells within the sample since these
are the ones capable of metabolism. Therefore, the serial dilution-agar plate method
was used to estimate the number of viable bacteria within a sample following a given
set of experimental conditions. This method was applied to each of the target bacterial
species using RCM agar plates and RCM broth.
The plate count procedure required five consecutive days to complete. A
summary of the tasks performed on each day was depicted in Figure 5.
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Figure 5 – Plate Count Procedure

• Streak plate for each specimen; Incubated
Day 1 • 4-10 mL tubes of RCM per specimen; Autoclaved

Day 2

• 1 RCM tube inoculated with single specimen;
Incubated

• 3 fresh RCM tubes each inoculated with 250 µL of
broth culture; Incubated
• 27-9 mL tubes of DI water, Autoclaved
Day 3
• 27 RCM agar plates; Poured
• 9 Serial dilutions in DI water per tube of RCM
Day 4 • Spread plate
Day 5

• Plate counts using QCount

2.8.1 Plate Count Procedure Day 1
On Day 1, streak plates for E. coli, B. fragilis, and C. perfringens were prepared
from the frozen stock cultures. The RCM agar plates were removed from the
refrigerator and placed in the incubator set at 37°C for 15 minutes to remove the chill.
One tube of frozen stock culture per species was moved from the -80°C freezer and
placed in the anaerobic chamber. An inoculation loop was dipped into the frozen stock
culture and the agar plate was streaked using the standard streak plate procedure for
isolated colonies. Plates were incubated upside down at 37°C for 24 hours under
anaerobic conditions. Incubating plates upside down ensured that colony formation and
growth were not interrupted by condensation that often forms on the lids of the plates
during incubation. In addition, four test tubes per specimen, each containing 10 mL of
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RCM broth were autoclaved at 121°C for 15 minutes. After sterilization, the tubes were
stored on the bench top at room temperature until they were needed in Day 2 and Day
3.
2.8.2 Plate Count Procedure Day 2
On Day 2, plates were examined for colony growth. The E. coli plate was full of
small, isolated, circular colonies. However, the B. fragilis and C. perfringens plates
were blank and looked as though they had not been previously streaked. An ATCC
representative suggested that the anaerobic specimens can often require 24-48 hours
for colony formation, so those plates were returned to the incubator for another 24 hours
at 37°C. An isolated colony of E. coli was transferred to a test tube of RCM. This tube
was incubated at 37°C for 24 hours under anaerobic conditions.
2.8.3 Plate Count Procedure Day 3
On Day 3, the agar plates of B. fragilis and C. perfringens were again examined
for colony formation. Plates were still free and clear. Most likely the RCM plates
contained dissolved oxygen content that inhibited growth for the anaerobic species.
Pre-reduced agar can be purchased from a microbiology supplies company, however
these plates were quite expensive and there was not adequate funding at the time to
support the purchase. Therefore the plate count procedure was continued solely for the
E. coli specimen.
Since the drug samples used in later experiments (Chapter 4) were dosed from
an inoculated broth media, it was important to determine the approximate number of
viable bacteria administered under experimental conditions. The E. coli test tube from
Day 2 was removed from the chamber and then vortexed for 30 seconds. The optical
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density (OD) was recorded using a spectrophotometer set at 600 nm. This served as a
numerical value for sample turbidity and allowed the amount of bacterial growth
between samples to be compared. Three of the remaining tubes of RCM broth were
inoculated with 250 μL of E. coli broth for replicate bacterial enumeration analysis.
Samples were incubated at 37°C for 24 hours under anaerobic conditions. After the
tubes were incubated, the supplies for the dilutions and plating for Day 4 were prepared.
9 mL of DI water was measured into 54 test tubes.
2.8.4 Plate Count Procedure Day 4
On Day 4, 3 sets of serial dilutions were prepared. Each inoculated test tube
from Day 3 served as Tube #1 for each Dilution Set. A test tube rack was set up with
the culture tube in position #1, followed by 9-9 mL tubes of sterile water labeled #2 #10. Tube #1 was vortexed for 10 seconds and then a 1mL aliquot from Tube #1 was
transferred by sterile pipet into Tube #2. After the transfer, the tip was discarded and
replaced with a new, sterile tip. This was done to ensure that there was no carryover
between dilutions. In similar fashion, Tube #2 was thoroughly mixed and then 1mL of
this solution was transferred into Tube #3. This process was repeated until all of the
dilutions were completed. This serial dilution method was applied to all 3 of the
anaerobic E.coli cultures from Day 3.
A pour plate method was originally attempted in the viable cell plate counts.
After making the dilution sets, 1 mL from each serial dilution tube was transferred to a
sterile petri dish. Fresh RCM agar was autoclaved and then cooled to approximately
55°C. The melted agar was poured over the top of the 1 mL aliquot of dilution sample.
The dish was carefully swirled to encourage mixing and even dispersal of the aliquot
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within the agar. The plates were incubated at 37°C for 24 hours under anaerobic
conditions.
There were several problems associated with this particular plate count method.
As the agar cooled to the requisite 55°C, the solution became clouded with solidifying
agar aggregates. This created a problem as the plates were poured because large
aggregations of agar would occasionally fall into the petri dishes. Not only did these
solids prevent desirable mixing of the aliquot sample with the agar, they also caused
some of the aliquot to be displaced out of the petri dish. This could affect the accuracy
of the plate count method.
In addition, bubbles and foam formed within the agar solution as it cooled. These
were transferred to pour plates along with the agar and made it difficult to distinguish
viable cell growth from the set bubbles and foam. This too would have had an impact
on the accuracy of the plate count. Finally, many bacteria display inhibited growth at
higher temperature. The optimal growth of Escherichia coli occurs at 37°C. Growth is
significantly hindered at temperatures greater than 45°C because the elevated heat
reduces the number of viable cells. Therefore, the raised agar temperature had the
potential to kill some of the viable cells, which likewise would have affected the
accuracy of the plate count. Thus, the spread plate method was chosen to be a better
choice with regards to the accuracy of the plate count results.
To optimize the spread plate method, the amount of sample transferred onto the
surface of the plate had to be determined. Aliquots of 1 mL and 100 μL produced large
landscapes of bacteria that coated the entire surface of the agar plate. No single
colonies were observed, even after serial dilution. Smaller aliquots of 50 μL, 25 μL, 10
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μL, 5 μL, and 2.5 μL were plated. While 50 μL and 25 μL still produced surface growth
(lawn) over the entirety of the plate, a smattering of single colonies was observed with
the 10 μL, 5 μL, and 2.5 μL aliquots. A new set of serial dilutions was performed and a
10 μL aliquot of each was plated and incubated. Plates were counted using the
Advanced QCount Automated Colony Counter. The majority of counts were within the
30-300 count required for accurate viable bacterial estimation. Therefore, the 10 μL
aliquot was chosen for future spread plating of E. coli.
The entire process was repeated from Day 1 to Day 4 for the E.coli sample under
anaerobic as well as aerobic conditions for comparison. On Day 4, after the dilutions
were prepared, the contents of Tube #3 (102 dilution) were mixed thoroughly. A 10 μL
aliquot was transferred from Tube #3 onto the surface of an RCM plate labeled 10 2.
The plate was placed on a petri dish turn table and the 10 μL aliquot distributed using a
plate spreader. This was done to ensure the agar surface was coated as evenly as
possible. This method was applied to each of the remaining Tube #4 - Tube#10 and
agar plates labeled 103 through 109 to complete Dilution Set #1. This method was
completed for the remaining dilution sets, and plates were incubated at 37°C for 24
hours under aerobic or anaerobic conditions. Figure 6 depicts the serial dilution
procedure.
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Figure 6 – Serial Dilutions and Spread Plates
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2.8.5 Plate Count Procedure Day 5
On Day 5, the colonies on the plates were counted using an Advanced QCount®
Automated Colony Counter. The system utilizes the patented ColorCount™ technology,
which is based on principles of color recognition. A lighted surface underneath the plate
and adjustable background plates allow the user to achieve optimal resolution and
achieve the most accurate plate count.
The plates were retrieved from their respective incubation chambers, and the
QCount® was used to count the colonies that formed on the surface of the plates. The
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plate was placed on the viewing surface agar-side down. The area multiplier was
adjusted to 10% so as to include colonies that formed near the outer edges of the agar.
Shutter speed was set to 1/250, while the size of the colonies adjusted to 0.2-20 mm.
Plates containing fewer than 30 colonies were considered too few to count
(TFTC) while plates containing more than 300 colonies were considered too numerous
to count (TNTC). The number of colonies was recorded for each plate using these
specifications. Table 10 summarized the plate count results for E. coli under aerobic
conditions in RCM while Table 11 summarized results under anaerobic conditions.
Table 10 – Aerobic Plate Count for E. coli
Dilution Factor
102
103
104
105
106
107
108
109

Set #1
TNTC
TNTC
TNTC
63
34
TFTC
TFTC
TFTC

Set #2
TNTC
TNTC
TNTC
143
29
TFTC
TFTC
TFTC

Set#3
TNTC
TNTC
TNTC
96
69
TFTC
TFTC
TFTC

Set #2
TNTC
TNTC
41
35
TFTC
TFTC
TFTC
TFTC

Set#3
TNTC
TNTC
31
33
TFTC
TFTC
TFTC
TFTC

Table 11 – Anaerobic Plate Count for E. coli
Dilution Factor
102
103
104
105
106
107
108
109

Set #1
TNTC
TNTC
58
39
TFTC
TFTC
TFTC
TFTC
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To calculate the approximate number of colony forming units (CFUs) in each
sample, the appropriate dilution factor was applied to the colony number count. In
Anaerobic Plate Count for E. coli the 104 plate contained 58 colonies. The calculation
was performed using Equation 8.
# Colonies = 58
Dilution Factor = 104
Volume of Dilution = 0.010 mL
Equation 8 – Determination of Colony Forming Units

Therefore, in this particular example,

Only plates that contained between 30-300 colonies were included in the analysis. The
aerobic CFU/mL data was reported in Table 12, and anaerobic CFU/mL data in Table
13.
Table 12 – Average Aerobic CFU/mL for E. coli
Dilution Factor
105
106
Set Average
Overall Average

Individual Plate Counts (CFU/mL)
6.3 x108
1.4 x109 9.6 x108
3.4 x109
2.9 x109 6.9 x109
2.0 x109
2.2 x109 3.9 x109
2.7 x109
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Table 13 – Average Anaerobic CFU/mL for E.coli
Dilution
104
105
Set Average
Overall Average

Individual Plate Counts (CFU/mL)
5.8 x107
4.1 x107
3.1 x107
3.9 x108
3.5 x108
3.3 x108
2.2 x108
2.0 x108
1.8 x108
2.0x108

As expected, the CFU/mL was greater for the aerobic preparations than the
anaerobic preparations. This was due to the fact that E. coli, a facultative anaerobic
species, grew best under aerobic conditions (average OD = 0.770), but was also
capable of growth under limited oxygen or anaerobic conditions to a lesser extent
(average OD = 0.664). These CFU/mL counts were near the approximate ranges of
viable populations found in the human digestive tract as reported by the NIH,
specifically the ileum (105 - 108) and colon (1010 - 1012).45

2.9.0 Cellular Lysis
2.9.1 Chemical Lysis
Several methods of cellular lysis were considered during method development.
Bug Buster® Protein Extraction Reagent by Novagen® is a type of chemical lysis
solution that chemically disrupts the cellular structure of E. coli to release proteins. The
solution consists of a mixture of Tris-buffer and detergents that perforate the cell wall.
This type of lysis was eliminated because RCM is a complex matrix, and addition of the
lysis solution would further complicate the extraction and analysis of the target
compounds and their metabolites.
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2.9.2 Microfluidizer
The microfluidizer is a type of homogenization instrument used to perform
mechanical lysis. The sample is driven into the interaction chamber where it encounters
a series of microchannels. High velocity flow of the sample creates high shear which
acts in combination with impact forces to disrupt the cellular structure.
A simple study was conducted using a Microfluidics M-110P to determine
potential effects of microfluidization on sample analysis. This instrument is depicted in
Figure 7.
Figure 7 – Microfluidics M-110P Microfluidizer

A vial with lid was weighed empty, and then weighed again after addition of 5 mL
of water. The water sample in each vial was passed through the microfluidizer three
times, and mass recorded after each pass. The purpose of this experiment was to
determine whether the instrumental design of the microfluidizer would have an effect on
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sample retrieval from the system. The change in mass between runs was designed to
identify changes in sample volume. The microfluidizer data is summarized in Table 14.
Table 14 – Effects of the Microfluidizer on Sample Volume
Tube #
1
2
3
4
5
6
7
8
9
10

Empty Vial + Lid (g)
6.40
6.38
6.40
6.51
6.41
6.41
6.41
6.39
6.41
6.43

+ 5mL DI H2O
11.33
11.27
11.35
11.50
11.30
11.25
11.36
11.32
11.37
11.38

Micro1 (g)
11.38
11.19
11.48
11.42
11.20
11.20
11.39
11.40
11.34
11.51

Micro2 (g)
11.32
11.23
11.43
11.40
10.88
11.14
11.44
11.39
11.23
11.56

Micro3 (g)
11.26
11.20
11.49
11.40
11.04
11.08
11.29
11.44
11.15
11.45

Averages of the microfluidizer analyses were taken and then subtracted from the
mass of vial, lid, and 5 mL of water. The average volume difference was determined to
be approximately 0.03 g ± 0.13 g. These results are detailed in Table 15. At room
temperature, the density of water is approximately 1 g/mL. Sample lysis by
microfluidizer therefore resulted in an average of 30 µL (± 130 µL) increase in sample
volume. This would have affected the concentration of samples prior to LC-MS/MS
analysis, which would have provided for inaccurate quantitation. In addition, there was
no way to guarantee proper flushing of the system between samples which could lead
to analyte carryover and sample contamination issues as well.
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Table 15 – Volume Differences after Microfluidizer Analysis
Tube #
1
2
3
4
5
6
7
8
9
10

5mL DI H2O (g)
4.93
4.89
4.95
4.99
4.89
4.84
4.95
4.93
4.96
4.95

Micro Average (g)
4.92
4.83
5.07
4.90
4.63
4.73
4.96
5.02
4.83
5.08

Difference (g)
+0.01
+0.06
-0.12
+0.09
+0.26
+0.11
-0.01
-0.09
+0.13
-0.13

2.9.3 Sonication
Sonication is another technique used in cellular lysis. Three samples containing
the benzodiazepine compounds and metabolites were prepared at 100 ng/mL and
quantified via LC-MS/MS. After analysis, the samples were sonicated for 10 minutes
and then reanalyzed. Post-sonication samples exhibited a concentration decrease for
all analytes and metabolites, ranging from -3.6 to -6.2 ng/mL. Because of the extent of
concentration decrease, sonication was likewise ruled out as a method of cellular lysis
for this research. Analysis was performed directly on bacterial samples without cellular
disruption or lysis.
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Chapter 3: Method Validation - Simultaneous Quantitation of
Diazepam, Flunitrazepam, and Metabolites in Reinforced
Clostridial Medium by Liquid Chromatography-Tandem Mass
Spectrometry
3.1.0 Introduction
Analytical and forensic toxicology revolve around the detection, identification, and
quantitation of compounds, particularly alcohol, pharmaceuticals, drugs of abuse, and
other toxic or lethal substances. There are many benzodiazepine methods available for
common matrices such as blood46-48, plasma49, hair50, 51, and urine51-53, but these
matrices do not provide all of the nutrients required to support the development and
proliferation of bacterial species. A medium like RCM, which was discussed in Table 2,
however, provides the nutrients required to promote bacterial growth and therefore
metabolism. Diazepam (DZ) and flunitrazepam (FLU) were chosen as the analytes of
interest because the human metabolites have been previously determined and chemical
standards were commercially available.
As detailed in Chapter 1, several studies have demonstrated that bacteria are
capable of metabolizing complex chemical substances including drugs of abuse. But,
before the metabolic effects of GI bacteria on DZ and FLU could be investigated and
compared to those of human metabolism, a method for the analysis and quantitation of
these benzodiazepines and their metabolites in RCM needed to be developed. To
perform these tasks with reliability and certainty, the method likewise needed to be
validated.
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The presented method includes development and validation of a novel LCMS/MS method for the detection, identification, and quantitation of DZ, FLU, and their
respective metabolites in RCM. Application of this method was discussed in Chapter 4.
DZ is classified as a Schedule IV benzodiazepine by the DEA, and acts as a
central nervous system (CNS) depressant.54 In the medical industry it is most
commonly known as Valium® and is usually administered in pill form, as a gel, or as an
injection. Street names include yellow V’s, blue V’s, foofoo’s, and Howards.
It is most frequently prescribed as a sedative or tranquilizer, but can also be used
in treatment of anxiety, convulsive disorders, and muscle spasms. Health effects
include drowsiness, vertigo, vomiting, depressed respiration, elevated heart rate, coma,
and death, particularly when the drug is abused.55 Known human metabolites of DZ
include nordiazepam (NDZ), oxazepam (OX), and temazepam (TZ). 46,48,50-52,56
FLU is also classified as a benzodiazepine and central nervous system
depressant. The DEA classifies it as a Schedule IV drug of abuse, however,
possession and distribution are considered Schedule I offenses. The manufacture,
importation, sale, and usage are illegal in the United States.24,54,56
By trade, FLU is labeled as Rohypnol®, and is commonly abused as a “date
rape” drug. On the street it may be referred to by a number of nicknames including
circles, forget-me-pill, La Rocha, lunch money, Mexican Valium, Reynolds, roach,
roofies, and wolfies to name just a few.24
FLU can be taken in pill form, or crushed to be either snorted or ingested. The
powder is colorless, odorless, and tasteless when mixed into beverages and food,
making it difficult to detect. Upon administration, it acts to incapacitate the victim and
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prevent resistance, often in cases of sexual assault. Health effects include drowsiness,
decreased anxiety, and impaired mental function. Excessive doses can result in
unconsciousness, anterograde amnesia, respiration suppression, and death. 24 Human
metabolites of FLU metabolites include 7-aminoflunitrazepam (7AM) and Ndesmethylflunitrazepam (NDES).47,48,51,53,57-59 47, 57,48, 51,53,58, 59

3.2.0 Materials and Methods
3.2.1 Materials
Reference standards for DZ, NDZ, OX, TZ, FLU, 7AM, and NDES as 1.0 mg/mL
and diazepam-d5 (DZ-d5), nordiazepam-d5 (NDZ-d5), oxazepam-d5 (OX-d5),
temazepam-d5 (TZ-d5), flunitrazepam-d7 (FLU-d7), 7-aminoflunitrazepam-d7 (7AM-d7),
and N-desmethylflunitrazepam-d4 (NDES-d4) as 100 µg/mL were purchased from
Cerilliant® (Round Rock, TX). Reagents and solvents consisted of 2-propanol (IPA)
(Optima™ LC/MS) purchased from Fischer Scientific (Pittsburgh, PA), HPLC grade
ethyl acetate (EA) from JT Baker® (Center Valley, PA), and formic acid (FA) eluent
additive for LC-MS and LC-MS CHROMASOLV® acetonitrile (ACN) and methanol
(MeOH) from Sigma-Aldrich® (St. Louis, MO). The Strata-X-Drug N 100µ Polymer RP
60 mg/3 mL cartridges used in sample preparation were obtained from Phenomenex®
(Torrance, CA). Compounds were separated using a narrow bore ZORBAX Eclipse
XDB-C8 (2.1 mm x 150 mm x 5 µm) column affixed with a ZORBAX Eclipse XDB-C8
(2.1 mm x 12.5 mm x 5 µm) guard cartridge from Agilent Technologies (Santa Clara,
CA). RCM was obtained from BD Difco™ (Sparks, MD).
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3.2.2 Sample Preparation
Several working solutions were used to prepare the dilution samples required for
method validation analyses. All working solutions were prepared in water/methanol
(60/40 v/v). An internal standard working solution consisting of the seven deuterated
analytes was prepared at 5000 ng/mL, and an analyte working standard consisting of
the seven analytes of interest at 10,000 ng/mL (WS1). Two additional working
standards were prepared by dilution of WS1 at 1000 ng/mL (WS2), and 10 ng/mL
(WS3).
The matrix consisted of ten 100 mL aliquots of RCM (3.8 g RCM in 100 mL of DI
water) that were pooled and then autoclaved at 121°C for 15 minutes. Calibrators and
sample dilutions were prepared in RCM from the appropriate working standard. The
final internal standard concentration in all 1 mL samples was 50 ng/mL.
3.2.3 Sample Extraction
An initial calibration curve was prepared from working solutions in buffer and
plotted at 0.01, 0.05, 0.1, 0.5, 1, 5, 10, 50, 100, 250, and 500 ng/mL. Calibration curves
for each analyte in buffer can be seen in Appendix A. Four different SPE methods were
evaluated for recovery of DZ, FLU, and metabolites. Reagents and solvents consisted
of acetonitrile (ACN), ethyl acetate (EA), isopropyl alcohol (IPA), formic acid (FA),
methanol (MeOH), and ammonium hydroxide (NH4OH). Details of the methods are
shown in Figures 8 and 9.
Samples were extracted from RCM at three concentrations 0.05, 0.5, and 100
ng/mL and then analyzed via LC-MS/MS. Results were evaluated based upon the
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retention time, accuracy, and ion ratios of analytes after extraction. SPE method 1 was
determined to be the best choice for extraction of all of the analytes of interest.
Figure 8 – SPE Method 1&2 for Diazepam, Flunitrazepam, and Metabolites

SPE 1

SPE 2

Cartridge: Strata-X-Drug N

Cartridge: Strata-X-Drug B

Wash

Dry

Elute

•ACN/H2O (20/80 v/v)

Wash

•10 minutes

Dry

•EA/IPA (85/15 v/v)

Elute

•0.1% FA
•MeOH/H2O (30/70 v/v)
•10 minutes
•2% NH4OH in
ACN/MeOH (1/1 v/v)

Figure 9 – SPE Method 3&4 for Diazepam, Flunitrazepam, and Metabolites

SPE 3

SPE 4

Cartridge: Strata-X-Drug N

Cartridge: Strata-X-Drug b

Wash

Dry

Elute

•H2O
•20% MeOH

Wash

•10 minutes

Dry

•100% MeOH

Elute
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•H2O
•15% MeOH
•10 minutes

•100% MeOH

Samples were extracted from RCM prior to analysis to minimize salts and other
compounds that could interfere with or inhibit LC-MS/MS analysis. The Strata-X-Drug N
cartridge is a polymeric reversed phase cartridge designed for neutral drugs of abuse
such as benzodiazepine compounds. Solid phase extraction was performed on a
vacuum manifold which can be seen in Figure 10.
Figure 10 – Solid Phase Extraction Vacuum Manifold

The manifold allowed for controlled extraction of up to 20 samples at a time.
Following extraction, samples were dried on another manifold under ultrapure nitrogen
supplied by a generator. The drying manifold apparatus is depicted in Figure 11.
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Figure 11 – SPE Nitrogen Dry Down Manifold

3.2.4 Instrumental Analysis
Analysis was performed using an Agilent G6490 Triple Quadrupole LC/MS
system equipped with iFunnel, G4226A HiP autosampler, G4220A binary pump, and
G1316C column compartment. Instrumentation can be seen in Figure 12.
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Figure 12 – Agilent G6490 Triple Quadrupole LC/MS

2 µL of sample was injected into the system at a flow rate of 0.250 mL/minute.
Mobile phases of water with 0.1% formic acid (A) and acetonitrile with 0.1% formic acid
(B) were used in a gradient elution program of 40% B to 70% B over 6 minutes, holding
at 70% B for 0.5 minutes, returning to original 40% B conditions over 0.1 minutes, and
then a column equilibration of 1.4 minutes for a total run time of 8 minutes. A post-run
time of 2 minutes at 40% B was included between runs to ensure column equilibration
before the next injection.
Samples were ionized via Agilent Jet Stream electrospray ionization source (AJS
ESI) in the positive mode. Parameters were optimized with the Agilent MassHunter™
Source and iFunnel Optimizer software using a 100 ng/mL extracted sample of DZ,
FLU, and their respective metabolites. The range of values explored for each
parameter, the increment by which conditions were changed, and the final optimized
value are summarized in Table 16. Other source parameters included the ΔEMV (400),
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fragmentor (380 V), and cell acceleration (2 V). Column temperature was maintained at
37°C and autosampler at 20°C.
Table 16 – Source and iFunnel Optimization for Diazepam, Flunitrazepam, and
Respective Metabolites in RCM
Parameter
Capillary Voltage (V)
Gas Temperature (°C)
Gas Flow (L/min)
Nebulizer (psi)
Sheath Gas Temperature (°C)
Sheath Gas Flow (L/min)

Range
500-6000
120-290
11-20
15-60
150-400
10-12

Increment
200
20°C
2
5
20°C
1

Optimized
3250
265
19
50
350
11

MassHunter™ Optimizer software was used to determine the best multiple
reaction monitoring (MRM) transitions for each analyte of interest as well as their
corresponding deuterated standards. The software provided up to four ion transitions
for each target analytes and metabolite compound. These tables can be seen in
Appendix B. All of the suggested ions were included in initial calibration. However, the
final quantifier and qualifier ions chosen for the method were those that demonstrated
the greatest signal response while also maintaining stable ion ratio across the
calibration range.
MRM data was only acquired in a narrow window based upon the retention time
of the analyte of interest. Because some of the ions had similar ion transitions, the
narrow range of acquisition increased the selectivity for each individual analytes.
Samples were quantified by comparing the peak area response ratio of the target
analyte to that of the corresponding deuterated standard. The retention time (RT),
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quantifier and (qualifier) MRM transitions, collision energy (CE), and ion ratio for each
set of analytes and corresponding deuterated standards is summarized in Table 17.
Table 17 – LC-MS/MS Parameters for Diazepam, Flunitrazepam, and Metabolites in
RCM

Analyte
DZ
DZ-d5
NDZ
NDZ-d5
OX
OX-d5
TZ
TZ-d5
FLU
FLU-d7
7AM
7AM-d7
NDES
NDES-d4

RT
(mins)
5.13

Q1
(m/z)
285.1

3.92

290.1
271.1

3.58

276.1
287.1

4.52

292.1
301.1

4.51

306.1
314.1

2.08

322.2
284.1

3.69

291.2
300.1
304.1

Q3
(m/z)
153.9
(222.1)
198.1
140.1
(208.1)
213.1
241.1
(162.9)
246.1
255.1
(176.9)
260.1
268.1
(239.1)
276.1
135.1
(226.2)
138.0
253.9
(197.9)
258.0

CE
(V)
25
25
29
21
25
25
17
37
17
17
37
17
21
33
25
25
29
25
21
37
21

Ion
Ratio
66.3

69.2

16.3

12.5

46.4

36.1

43.7

3.2.5 Method Validation
Definitions and guidelines used in method validation were detailed in section
1.5.0. A full validation including a calibration model as well as interference studies,
carryover effects, ionization suppression/ enhancement, recovery, bias, precision, limit
of detection (LOD), limit of quantitation (LOQ), dilution integrity, stability, and robustness
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of the method were evaluated. The MRM output for the method was depicted in Figure
13.
Figure 13 – MRM of Diazepam, Flunitrazepam, and Respective Metabolites in RCM

7AM

FLU

NDES

DZ
NDZ

OX
TZ

3.3.0 Results and Discussion

3.3.1 Calibration Model
Calibrators and quality control samples (QC) were prepared from the appropriate
working solutions. The final calibration model consisted of a 10-point calibration at 0.05,
0.1, 0.5, 1, 5, 10, 50, 100, 250, and 500 ng/mL for the analytes of interest and 50 ng/mL
for the deuterated standards extracted from RCM. QCs were established at 1 (low) and
100 ng/mL (high). The calibration range, correlation coefficient, LOD and LOQ for each
analyte can be seen in Table 18. The calibration model was one of the most important
features of method validation because subsequent analyses and quantitation were
based upon this model.
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Table 18 – Calibration Range, Correlation, LOD, and LOQ for Diazepam,
Flunitrazepam, and Metabolites in RCM
Analyte
DZ
NDZ
OX
TZ
FLU
7AM
NDES

Calibration Range
(ng/mL)
0.5-500
0.5-500
1.0-500
0.5-500
0.5-500
0.1-500
0.5-500

2

R
0.996
0.996
0.995
0.996
0.995
0.996
0.995

LOD
(ng/mL)
0.1
0.5
1.0
0.5
0.5
0.1
0.5

LOQ
(ng/mL)
0.5
0.5
1.0
0.5
0.5
0.1
0.5

3.3.2 Carryover Analysis
Carryover analysis is a component of method validation advocated by SWGTOX.
Because some LOQ values were as low as 0.1 ng/mL, carryover effects from high
concentration samples posed a real threat to the accuracy of subsequent sample
quantitation. Carryover analysis was conducted at three concentrations including the
highest calibration point of 500 ng/mL and two points at higher concentration: 700
ng/mL and 900 ng/mL. An extracted blank was injected after each sample to analyze
carryover effects.
Analysis of previously established identification criteria as well as agreement
between experimental and theoretical concentrations indicated that the presented
method was valid up to at least 900 ng/mL using the linear calibration model. However,
analysis of the blank injections proved that carryover was present for all target analytes
at higher concentrations. To counteract the effects of carryover, an extracted blank
sample was run after every sample injection.
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3.3.3 Interference Studies
Interference studies were a component of method specificity as defined in
section 1.5.3. Ten samples of RCM matrix were pooled for validation interference
studies. Blank matrix samples were extracted and analyzed to identify matrix effects
that could potentially affect analysis of the analytes of interest. While there was some
evidence of matrix effect based upon qualitative analysis, the established identification
criteria of RT, peak shape, and ion ratios were not satisfied in blank specimens.
Blank matrix was also spiked at 50 ng/mL for each deuterated standard to
address possible interferences arising from similar fragmentation patterns of target
analyte and corresponding deuterated standard as well as potential internal standard
impurities. The blank matrix samples containing deuterated standards likewise
exhibited negligible interference based on the established identification criteria.
3.3.4 Ionization Suppression/Enhancement and Recovery
Ionization suppression and enhancement studies were combined with ME, RE,
and PE studies. These were defined in Section 1.5.3.2 as components of method
specificity. Samples were prepared in duplicate and analyzed in triplicate for Sets A, B,
and C at each concentration level. Equations 1-3 as defined in Chapter 1 were used to
calculate % ME, % RE, and % PE for each analyte. Results are summarized in Table
19.
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Table 19 – Matrix Effects, Recovery, and Process Efficiency for Diazepam,
Flunitrazepam, and Metabolites in RCM
Analyte

DZ

ND

OX

TZ

FLU

7AM

NDES

ME (%)
RE (%)
PE (%)

99.1
95.3
94.5

97.1
97.0
94.2

High (100 ng/mL)
97.2
97.6
96.9
96.4
94.7
95.4
93.7
92.4
92.5

98.8
97.8
96.6

97.9
95.5
93.5

ME (%)
RE (%)
PE (%)

92.2
119.5
110.2

118.9
117.8
140.1

Low (1 ng/mL)
87.6
93.8
91.1
117.9 118.2 114.6
103.4 110.9 104.4

94.8
116.5
110.4

99.3
117.6
116.8

Matrix effects ranged from 97-99% at high concentrations but demonstrated
greater variation at lower concentrations from 91-119%. At low concentration, all of the
target analytes exhibited ionization suppression from interfering compounds in the
matrix except for NDZ, which exhibited ionization enhancement. The suppression and
enhancement effects were likely due to compounds within the RCM matrix that coeluted with the target analytes thereby affecting the ionization efficiency.
Recovery ranged from 95-98% at high concentration. At low concentration, all of
the analytes exhibited recoveries over 100%, ranging from 115-119%. This indicated
that samples spiked with analytes and deuterated standards prior to extraction (Set C)
exhibited higher experimental concentrations than samples spiked after the extraction
process (Set B). This was likely due to matrix components that were not removed
during SPE. This explanation was supported by the ionization enhancement effects
seen in % ME at low concentrations.
Analytical recovery was representative of the effectiveness of the sample
preparation technique. Strata-X-Drug N cartridges were chosen for their selectivity
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towards neutral drugs of abuse such as benzodiazepines. The SPE method included
an aqueous wash step with acetonitrile/water (20/80 v/v) which helped to remove much
of the salt content of the media. Samples were eluted with EA/IPA (85/15 v/v), which
enhanced the separation of remaining polar compounds in the matrix from the analytes
of interest. Since the SPE method focused on removal of polar matrix components and
salts, the recovery enhancement was likely due to nonpolar media components
coeluting with the analytes of interest.
PE compared the spiked samples that went through the full extraction method
(C) to the samples prepared in neat buffer (A). These values and ranged from 92-97%
at high concentrations and 103-140% at lower concentrations. PE can also be
considered as the combined effects of ME x RE, which accounted for the greater range
of variation, especially for NDZ which was more sensitive to matrix effects.
3.3.5 Bias and Precision
Bias and precision studies were studied at four representative concentrations
0.500 (low), 1 (medium/low), 50 (medium), and 500 (high) ng/mL for DZ, NDZ, TZ, FLU,
7AM, and NDES, and three concentrations 1 (low), 50 (intermediate), and 500 ng/mL
(high) for OX. Analysis was adjusted for OX because the LOD and LOQ values were
higher than the other analytes at 1ng/mL. Five samples were prepared and extracted
for each concentration and analyzed in triplicate.
The bias of the method was defined in Section 1.5.5 and calculated using
Equation 5. Generally, the higher concentration sample sets had the narrowest range
of values, which became broader as the concentration decreased toward analyte LOQ.
Even though the acceptable bias range of ±20% is the same for all concentration levels,
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small changes in sample extraction and preparation as well as instrumental response
had a greater effect on lower concentrations than higher concentrations, causing the
range of values to broaden.
Precision and repeatability of the method were determined using the same data
set as bias analysis. Precision was defined in Section 1.5.6 and calculated as withinrun precision via Equation 6. Repeatability of the method was defined in Section 1.5.7
and calculated as between–run precision using Equation 7. The acceptable range for
both bias and precision was ±20% and values were recorded in Table 20. Both sets of
precision values followed the same trend as that seen with bias with narrowest range of
values seen at higher concentrations.
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Table 20 – Bias, Within-Run and Between-Run %CV for Diazepam, Flunitrazepam, and
Respective Metabolites in RCM
Bias and Precision
Analyte

DZ

ND

TZ

FLU

7AM

NDES

Bias
Within-Run
Between-Run

-2.1
1.8
2.8

High (500 ng/mL)
-3.6
-3.0
-2.0
2.3
1.8
2.0
2.8
2.7
2.7

-3.4
2.6
2.9

-2.5
1.5
2.9

-1.7
2.3
3.8

Bias
Within-Run
Between-Run

-3.6
1.7
2.8

Medium (50 ng/mL)
-5.5
-9.9
-8.5
2.9
1.8
2.4
3.6
2.1
3.4

-10.5
1.9
2.7

-5.5
1.9
2.5

-8.1
2.0
3.4

Bias
Within-Run
Between-Run

-8.9
4.4
5.4

Medium/Low (1 ng/mL)
1.3
-12.1 -17.6 -14.4
4.4
11.3
5.0
5.2
5.9
11.7
5.9
5.9

-8.0
2.1
4.0

-10.7
5.5
5.0

-14.9
2.1
4.0

-4.5
12.2
9.5

Bias
Within-Run
Between-Run

-5.7
3.6
4.6

OX

Low (0.500 ng/mL)
-6.8
NA
-9.7
4.7
N/A
10.5
6.0
N/A
8.1

-13.1
10.2
6.6

3.3.6 Dilution Integrity
To determine dilution integrity (Section 1.5.11), bias and precision studies were
repeated for the diluted samples. This was an important feature of method validation
because biotransformation samples were spiked at 1000 ng/mL (Chapter 4). Common
dilution ratios of 1:2 for an 800 ng/mL sample and 1:5 for a 1000 ng/mL sample were
examined. Five samples per concentration level were prepared, extracted, and
analyzed in triplicate. Both sets of dilutions maintained the require identification criteria.
Bias ranged from -8.1 to 7.9% across both dilution sets while within-run precision
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ranged from 1.8-5.4% and between run precision from 2.1-3.9%. Bias and precision
data for the dilution samples was summarized in Table 21. Future dilutions could be
prepared at either 1:2 or 1:5 and maintain sample integrity.
Table 21 – Dilution Integrity for 1:2 and 1:5 Sample Dilutions
Dilution Integrity
Bias
Within-Run
Between-Run

0.55
1.8
2.1

1:2 (800:400 ng/mL)
6.7
2.7
-2.6
3.6
2.7
3.9
2.2
2.7
2.4

Bias
Within-Run
Between-Run

1.4
4.4
3.1

1:5 (1000:200 ng/mL)
7.9
1.5
-3.3
3.2
4.8
5.4
3.6
3.9
3.4

-1.9
4.3
3.1

-5.6
3.2
2.2

-6.9
4.0
2.6

-1.1
3.8
2.6

-3.4
4.0
3.0

-8.1
3.3
3.3

3.3.7 LOD and LOQ
The LOD and LOQ criteria are summarized in sections 1.5.8 and 1.5.9,
respectively. Values ranged from 0.100 to 1 ng/mL for DZ, FLU, and metabolites.
Results were included in Table 18. DZ and 7AM achieved the lowest LOD and LOQ
values at 0.1 ng/mL. However, while DZ achieved acceptable RT, peak shape, and ion
ratios at 0.1 ng/mL which satisfied LOD requirements, the bias exceeded ± 20%. LOQ
requirements were fulfilled at 0.5 ng/mL for DZ. The remaining analytes of interest
achieved LOQ values ≤ 0.5 ng/mL with the exception of OX.
OX samples were within the appropriate RT window and maintained good peak
shape. However, the ion ratio analysis prevented detection and quantitation limits from
being confirmed with certainty at lower concentrations. This was supported by data
obtained for interference analysis in Section 3.3.4. The % ME decreased from 97.2% at
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high concentration to 87.6% at low concentration, indicating that ionization suppression
of OX was greater at low concentrations.
Additionally, the % RE increased from 96.4% (high) to 117.9% (low). This
supported the inconsistent ion ratios seen in analysis of LOD and LOQ determination.
The accuracy and bias of OX samples at low concentrations were within the acceptable
± 20%. However, the ion ratios at low concentrations increased. Ion ratios were
calculated as a ratio of response between qualitative ion: quantitative ion. Increase in
ion ratio indicated an increase in response of the 162.9 m/z transition in comparison to
that of the 241.1 m/z transition. This could have been indicative of a matrix component
with a similar set of ion transitions, which affected response of OX.
3.3.8 Stability
The FT and processed sample stability were both assessed as part of the
method validation. FT stability was conducted at two concentrations 500 ng/m (high)
and 1 ng/mL (low). The FT cycle analysis for 500 ng/mL was expressed in Figure 14.
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Figure 14 – Freeze-Thaw Stability for Diazepam, Flunitrazepam, and Respective Metabolites in RCM at 500 ng/mL

520.0
Concentration (ng/mL)
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TZ
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FT 1
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FT 3

At high concentration the acceptable range of ±20% was between 400-600
ng/mL. NDZ, OX, FLU, NDES exhibited a slight increase in response between FT1 and
FT2 while the other compounds showed a decrease. Since an extracted matrix blank
was injected between each sample, these effects were not due to carryover. The
results were likely due to fluctuations in instrumental response. All analyte
concentrations decreased from FT2 to FT3, which was expected. However none of the
compounds fell below 400 ng/mL, which indicated that samples would retain stability
through 3 FT cycles at high concentration.
The freeze-thaw cycle for 1 ng/mL samples was depicted in Figure 15. At low
concentration the acceptable range was between 0.8 and 1.2 ng/mL. NDZ and NDES
again displayed an increase in response between FT1 and FT2 while the other analytes
decreased in concentration. All analyte concentrations decreased between FT2 and
FT3. Unlike what was seen at high concentration, responses for OX, TZ, and FLU fell
below 0.8 ng/mL. For this method, it was therefore concluded that samples may
undergo up to two FT cycles and still maintain stability criteria, but cannot be analyzed
after three FT cycles with certainty.
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Concentration (ng/mL)

Figure 15 – Freeze-Thaw Stability for Diazepam, Flunitrazepam, and Respective Metabolites in RCM at 1 ng/mL

1.15
DZ
1.05

NDZ

0.95

OX
TZ

0.85

FLU

0.75

7-AM
NDES

0.65
FT 1

FT 2

70

FT 3

The stability of processed samples was studied to address possible effects of
large sample batches or instrumental malfunctions that would prevent samples from
being analyzed immediately. Stability studies were conducted at two concentrations
500 ng/mL (high) and 0.500 ng/mL (low). Two samples were prepared in RCM at each
concentration, extracted, reconstituted, and analyzed in triplicate over 48 hours. Eleven
samples were run at time 0, 3, 6, 9, 12, 15, 18, 24, 30, 36, and 48 hours. For high
concentration, analyte response ranged from FLU at 477 ng/mL to OX at 563 ng/mL.
The processed samples remained stable for at least 48 hours for all analytes of interest.
Results can be seen in Figure 16.
For low concentration samples at time 48 hours, responses ranged from 7AM at
0.462 ng/mL and DZ at 0.534 ng/mL. Results can be seen in Figure 17. Based on the
processed sample stability studies, all analytes of interest maintained stability for at
least 48 hours.
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Figure 16 – Processed Sample Stability for Diazepam, Flunitrazepam, and Respective Metabolites in RCM at 500 ng/mL
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Figure 17 – Processed Sample Stability for Diazepam, Flunitrazepam, and Respective Metabolites in RCM at 0.5 ng/mL
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3.3.9 Robustness
Robustness of the method was defined in Section 1.5.13 and determined by
slight changes in the buffer composition and column temperature. Samples were run at
0.5, 5, 50, 250, and 500 ng/mL for each variable. Buffer A for this benzodiazepine
method consists of water with 0.1% formic acid. The effect of changes in buffer
composition was assessed by running a series of samples with buffers containing
0.05%, 0.1%, and 0.15% formic acid. Samples with the 0.05% and 0.1% formic acid
buffer maintained identification criteria and experimental concentrations were within
±20% for all concentration levels.
The 0.15% formic acid samples maintained identification and accuracy criteria for
5, 50, 250, and 500 ng/mL but ranged from 108-141% for the 0.5 ng/mL sample. The
same samples were used for the buffer composition studies, so this effect was not due
to differences in sample preparation or extraction. RT, peak shapes, and ion ratios all
experienced more fluctuation with this buffer composition for all analytes. Peak shapes
at the lowest concentration of 0.5 ng/mL were no longer Gaussian which affected the
accuracy of quantitation.
Column temperature for the validated method was held at 37°C. The effects of
column temperature were analyzed at 30°C, 37°C, and 40°C. Identification and
accuracy criteria were met for DZ, OX, TZ, FLU, 7AM, and NDES for all concentration
levels and temperatures. The 0.5 ng/mL sample for OX at 40°C robustness study
exceeded the ±20% theoretical concentration allotment at 134%. However, the LOD
and LOQ for OX were 1 ng/mL, so this analyte could not have been detected or
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quantified at 0.5 ng/mL with certainty using this method regardless of column
temperature.
In addition to buffer composition and column temperature, an alternate analyst
prepared samples at the five concentration levels for analysis. Identification criteria were
met at all concentration levels.

3.4.0 Conclusions
Validation of this method was essential for further studies on the
biotransformation of drugs of abuse by bacteria grown in RCM. This LC-MS/MS
method was used to analyze and quantify the bacterial biotransformation phenomena
presented in Chapter 4. It will also be used to compare the bacterial products to those
of normal human metabolism.
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Chapter 4: Detection and Quantitation of Diazepam and
Flunitrazepam Metabolites Produced by Anaerobic Bacterial
Species in Reinforced Clostridial Medium using Liquid
Chromatography-Tandem Mass Spectrometry
4.1.0 Introduction
The ability of bacterial species to transform a variety of complex compounds has
been well documented. Some of these species are native to the human GI tract and
may have the potential to cause biotransformations that affect the ratio of compound-tometabolite concentrations within the human body. Investigation of these possibilities
required optimization of bacterial growth conditions, a method of analyte extraction from
the nutrient medium RCM, and an LC-MS/MS method for analysis and quantitation of
experimental results. Bacterial growth conditions and methods were optimized in
Chapter 2 of this document, and the SPE and LC-MS/MS methods were developed and
validated in Chapter 3.
Chapter 4 is essentially the culmination and application of the previous work.
Experiments focused on the effects of E. coli, B. fragilis, and C. perfringens on DZ, FLU,
and their metabolites in RCM under anaerobic conditions. DZ and FLU are
benzodiazepine compounds of forensic importance and interest. They were selected
for biotransformation studies because the human metabolites have been previously
identified and reference standards were commercially available.
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4.2.0 Diazepam Metabolism
Human metabolites of DZ include nordiazepam (NDZ), oxazepam (OX), and
temazepam (TZ) and can be seen in Figure 17.46,48,50-52,56,60-62 46,48,50-52,56,50, 52, 60,61,62
Figure 18 – Human Metabolites of Diazepam

Diazepam
-CH3

+ OH

Nordiazepam

Temazepam

+ OH

-CH3

Oxazepam

77

4.3.0 Flunitrazepam Metabolism
Human metabolites of FLU include 7-aminoflunitrazepam (7AM) and Ndesmethylflunitrazepam (NDES) and can be seen in Figure 18.47,48,51,53,57-59 47,48, 51,53,57-59
The 3-hydroxyflunitrazepam metabolite was not included in analysis because it was not
available at the time of method development and validation.
Figure 19 – Human Metabolites of Flunitrazepam
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4.4.0 Materials
Escherichia coli (33985), Bacteroides fragilis (29771), and Clostridium
perfringens (19574) were purchased from the American Type Culture Collection®
(Manassas, VA). BD Difco™ Reinforced Clostridial Medium and sterile 15 mL
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polypropylene BD Falcon™ tubes were obtained from BD Diagnostic Systems (Sparks,
MD). The Vinyl Anaerobic Chamber (Type A) with automatic airlock and incubator
produced by Coy Laboratory Products Inc was used for anaerobic incubation (Grass
Lake, MI). Reference standards were purchased from Cerilliant® (Round Rock, TX) as
1.0 mg/mL for DZ and FLU. All other materials used in extraction and LC-MS/MS
analysis were detailed in Section 3.2.0.

4.5.0 Methods
4.5.1 Conditions
E.coli, B. fragilis, and C. perfringens required specific environmental growth
conditions. These were optimized and discussed in Section 2.6.0.

4.5.2 Media
The RCM was prepared according to manufacturer instructions by dissolving 38
grams of dehydrated RCM in purified water. The medium was autoclaved at 121°C for
15 minutes. RCM was transferred to the anaerobic chamber and stored with the cap
loosened for 48 hours to promote evacuation of dissolved oxygen. This was particularly
important for growth of C. perfringens. After evacuation, RCM was capped and stored
at room temperature until further use.
4.5.3 Bacterial Sample Preparation
One of the frozen stock cultures described in Section 2.7.0 was removed from
storage and placed in the anaerobic chamber. The contents were transferred to a
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sterile 15 mL tube containing 10 mL of RCM and incubated with the lid loosened at
37°C for 48 hours. This process was repeated for all three bacterial species.
Blanks and biotransformation samples were all prepared in 10 mL of RCM. They
were dosed with analyte and/or bacterial specimen as outlined in Table 22.
Immediately after the samples were prepared, they were vortexed for 30 seconds,
inverted 10 times, and vortexed for an additional 30 seconds to ensure thorough mixing.
A 200 µL pre-incubation aliquot of each sample was transferred to an Eppendorf tube
and transported out of the anaerobic chamber for analysis. Samples were incubated
with the lid loosened at 37°C for 48 hours.
Table 22 – Sample Preparation
Sample
DZ Blank
FLU Blank
E. coli Blank
B. fragilis Blank
C. perfringens Blank
Mixed Culture Blank
DZ + E.coli
DZ + B. fragilis
DZ + C. perfringens
DZ + Mixed Culture
FLU + E.coli
FLU + B. fragilis
FLU + C. perfringens
FLU + Mixed Culture

DZ
(ng/mL)
1000
1000
1000
1000
1000
-

FLU
(ng/mL)
1000
1000
1000
1000
1000

E. coli
(µL)
250
100
250
100
250
100

B. fragilis
(µL)
250
100
250
100
250
100

C. perfringens
(µL)
250
100
250
100
250
100

The 200 µL pre-incubation aliquot (concentration 1000 ng/mL) was combined
with 10 µL of internal standard working solution (5000 ng/mL) and 790 µL
water/acetonitrile (60/40 v/v) buffer for a 1:5 dilution (Section 3.3.6). Pre-incubation
samples were immediately extracted and then analyzed via LC-MS/MS.
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Post-incubation, samples were removed from the chamber after 48 hours,
vortexed for 30 seconds, inverted 10 times, and vortexed for an additional 30 seconds
to ensure uniform composition throughout. The OD was measured for comparison to
the values obtained during the plate count method. Another 200 µL aliquot of each
sample was extracted and analyzed as the post-incubation counterpart. Instrumental
parameters, MRM transitions, SPE, and the LC-MS/MS method of analysis are all
described in Chapter 3.

4.6.0 Results and Discussion
Two sets of DZ and FLU biotransformation experiments were conducted while
the LC-MS/MS method was being developed and validated. Samples were prepared
following the same guidelines as those described in Table 22 and stored in the freezer
until they could be extracted and analyzed. These sets of experiments were analyzed
but both of them were rendered useless.
In the first set, nearly all of the media samples inoculated for biotransformation
studies failed to support bacterial growth. E. coli was the only specimen to produce any
sort of turbidity, as evidenced by the resultant OD values. However, even these
samples were barely distinguishable from the RCM blanks. Purging RCM in the
anaerobic chamber for 48 hours after sterilization eliminated this problem, and all of the
bacterial species demonstrated prominent growth.
The second set of samples was analyzed via LC-MS/MS. However, there was
no way to determine the original concentrations of the samples prior to incubation. Any
evidence of biotransformation could not be definitively attributed to the bacterial
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species. Decrease in theoretical concentration could have been a result of incomplete
dosing. It could also have been due to unassisted degradation of the analyte under
experimental conditions. This dilemma was solved by implementing analysis of preincubation as well as post-incubation aliquots of the samples.
4.6.1 Bacterial Blanks
A series of bacterial blanks were prepared with aliquots of E. coli, B. fragilis, C.
perfringens, or a mixture of the three without analytes of interest. None of the bacterial
specimens produced interferences with the target analytes that satisfied identification
and confirmation requirements of peak shape, retention time, ion ratio, and that were
above the analyte LOQ.
4.6.2 Diazepam Blanks
A series of analyte blanks was prepared in RCM and incubated alongside
samples inoculated with bacteria. Two blanks per analyte were spiked with either DZ or
FLU and incubated at 37°C for 48 hours. Samples were evaluated via OD
measurement to ensure that the media remained clear and turbidity-free over the
course of the experiments. Pre- and post-incubation aliquots were extracted and
analyzed via LC-MS/MS. Analytes and metabolites were evaluated for acceptable peak
shape, retention time, ion ratios, and S/N ≥ 3 for detection, and with bias and precision
within ±20% for quantitation.
Analysis of DZ Drug Blank 1 (Table 23) demonstrated an average change in
concentration of -11.1 ± 3.2 ng/mL and DZ Drug Blank 2 (Table 24) an average
difference of -21.4 ± 3.6 ng/mL. However, NDZ, OX, nor TZ registered an increase from
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pre- to post-incubation concentrations to account for the DZ conversion. Standard
deviations were determined at the 95% confidence interval.
The RCM for both DZ blank samples maintained its clarity and did not exhibit any
characteristics that would indicate bacterial presence. The discrepancy in mass
balance between pre- and post-incubation samples suggested that DZ must undergo a
partial, unassisted degradation to a compound other than those found in normal human
metabolism. This was likely due to molecule instability when incubated at 37°C for 48
hours.
Table 23 – Pre- and Post-Incubation Analysis: Diazepam Drug Blank 1
Sample
Pre DZ Blank 1
Post DZ Blank 1
Δ Concentration Average

Concentration (ng/mL)
DZ
NDZ
OX
165.3 ± 0.5 0.1 ± 0.0 0.0 ± 0.0
154.2 ± 3.1 0.0 ± 0.0 0.0 ± 0.0
-11.1 ± 3.2 0.0 ± 0.0 0.0 ± 0.0

TZ
0.0 ± 0.0
0.0 ± 0.0
0.0 ± 0.0

Table 24 – Pre- and Post-Incubation Analysis: Diazepam Drug Blank 2
Sample
Pre DZ Blank 2
Post DZ Blank 2
Δ Concentration Average

Concentration (ng/mL)
DZ
NDZ
OX
187.9 ± 2.6 0.1 ± 0.0 0.0 ± 0.0
166.4 ± 1.2 0.0 ± 0.0 0.0 ± 0.0
-21.4 ± 3.6 0.0 ± 0.0 0.0 ± 0.0

TZ
0.0 ± 0.0
0.0 ± 0.0
0.0 ± 0.0

A literature search of previously published research identified several possibilities
for alternative metabolites including 4’-OH DZ (metabolite of DZ) and 4’-OH norezepam,
a metabolite of NDZ.63 The metabolic scheme was depicted in Figure 20.
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Figure 20 – Alternative Metabolites of Diazepam and Nordiazepam
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4.6.3 Effects of E.coli on DZ
RCM samples prepared for biotransformation studies were spiked with an
analyte of interest at 1000 ng/mL as well as either E. coli, B. fragilis, C. perfringens, or a
mixture of the three. Each sample was prepared in duplicate and analyzed in triplicate.
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Pre- and post-incubation aliquots were taken for analysis and the change in
concentration results were calculated.
The RCM in DZ biotransformation studies inoculated with E. coli demonstrated
the marked turbidity indicative of prominent bacterial growth. As discussed in Section
2.8.0, a 250 µL aliquot of E. coli resulted in approximately 2.0 x 108 CFU/mL after
anaerobic incubation, which was comparable to estimates of bacterial enumeration in
the human ileum and colon. The OD and turbidity of RCM supported that viable E. coli,
those capable of growth, division, and metabolic activity, were present in the
biotransformation study samples.
Analysis of the effects of E. coli on DZ concentration demonstrated an average
change in concentration of –28.1 ± 2.7 ng/mL in sample 1 and -40.0 ± 3.0 ng/mL in
sample 2. These results were summarized in Table 25 and Table 26, respectively.
Table 25 – Pre- and Post-Incubation Analysis: Effects of E. coli on Diazepam 1
Sample
Pre E.coli 1
Post E.coli 1
Δ Concentration

Concentration (ng/mL)
DZ
NDZ
OX
191.8 ± 2.1 0.1 ± 0.0 0.0 ± 0.0
163.7 ± 1.5 0.0 ± 0.0 0.0 ± 0.0
-28.1 ± 2.7 0.0 ± 0.0 0.0 ± 0.0
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TZ
0.0 ± 0.0
0.0 ± 0.0
0.0 ± 0.0

Table 26 – Pre- and Post-Incubation Analysis: Effects of E. coli on Diazepam 2

Sample
Pre E.coli 2
Post E.coli 2
Δ Concentration

Concentration (ng/mL)
DZ
NDZ
OX
197.9 ± 1.6 0.1 ± 0.0 0.0 ± 0.0
157.9 ± 1.7 0.0 ± 0.0 0.0 ± 0.7
-40.0 ± 3.0 0.1 ± 0.0 0.4 ± 0.7

TZ
0.0 ± 0.0
0.0 ± 0.0
0.0 ± 0.0

As seen in the drug blank samples, neither NDZ, OX, nor TZ registered a
detectible or quantifiable increase from pre- to post-incubation concentrations. In
sample 2, instrumental response did indicate a decrease in ND concentration of 0.1 ±
0.0 ng/mL, and an increase in OX concentration of 0.4 ± 0.7 ng/mL between pre- and
post-incubation samples. However, the ion ratios for NDZ and OX were not within the
acceptable range of ± 20% as defined in Table 17. The experimental values were also
below the LOD and LOQ values established in the method validation (Section 3.3.7,
Table 18) for both analytes. Without fulfillment of these components along with RT and
peak shape, an analyte cannot be detected or confirmed with certainty. Therefore, the
changes in concentration for NDZ and OX were insignificant.
The average change in concentration between pre- and post-incubation DZ
blanks ranged from -11.1 to -21.4 ng/mL while samples incubated with E. coli ranged
from -28.1 to -40.0 ng/mL. The discrepancies between blank and biotransformation
study samples, though slight, indicated that there may be additional factors contributing
to the transformation of DZ when incubated with E.coli. While the majority of DZ
disappearance could be attributed to the proposed unassisted degradation, the mass
balance of the reaction suggested that DZ was being converted to a compound other
than the human metabolites NDZ, OX, and TZ monitored. In this case, E. coli
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possessed a specific enzyme or combination of enzymes that were capable of cleaving
DZ to form some type of alternative minor metabolite.
4.6.4 Effects of B. fragilis on DZ
Turbidity in B. fragilis samples was comparable to that seen in the bacterial blank
and E. coli biotransformation incubations. Analysis of the effects of B. fragilis on DZ
demonstrated an average change in DZ concentration between pre- and postincubation of -46.2 ± 2.2 ng/mL in sample 1 and -23.9 ± 3.5 ng/mL in sample 2. These
results were summarized in Table 27 and Table 28, respectively.
Table 27 – Pre- and Post-Incubation Analysis: Effects of B. fragilis on Diazepam 1
Sample
Pre B. fragilis 1
Post B. fragilis 1
Δ Concentration

Concentration (ng/mL)
DZ
NDZ
OX
179.7 ± 1.5
0.1 ± 0.0
0.0 ± 0.0
133.5 ± 0.8
0.0 ± 0.0
0.0 ± 0.0
-46.2 ± 2.2 -0.1 ± 0.0 0.0 ± 0.0

TZ
0.0 ± 0.0
0.0 ± 0.0
0.0 ± 0.0

Table 28 – Pre- and Post-Incubation Analysis: Effects of B. fragilis on Diazepam 2
Sample
Pre B. fragilis 2
Post B. fragilis 2
Δ Concentration

Concentration (ng/mL)
DZ
NDZ
OX
172.5 ± 3.3 0.1 ± 0.0 0.0 ± 0.1
148.6 ± 0.9 0.1 ± 0.0 0.0 ± 0.0
-23.9 ± 3.5 0.0 ± 0.0 0.0 ± 0.0

TZ
0.0 ± 0.0
0.0 ± 0.0
0.0 ± 0.0

In agreement with the analyte blank and biotransformation studies with E. coli,
the mass balance of DZ was affected; however, NDZ, OX, nor TZ registered a response
greater than their respective LOD or LOQ in incubations with B. fragilis. As suggested
with the E. coli studies, the majority of DZ disappearance could be attributed to the
proposed unassisted degradation. But the change in DZ concentration is greater than
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that observed in the analyte blanks. This may have resulted from an enzymatic reaction
utilized by B. fragilis to cleave DZ and produce an alternative metabolite. It is unclear
whether E.coli and B. fragilis employed the same enzyme to account for the
discrepancy between the drug blank and bacterially inoculated samples or if the DZ
cleavage was attributed to species-specific enzymes.
The proposed alternative metabolites could be added to the LC-MS/MS method
and monitored for changes between pre- and post-incubation analysis. A kinetic study
on the rate of disappearance of DZ might also provide valuable information that could
aid in compound identification. Additionally, analysis of the post-incubation sample via
LC-MS/MS in full scan mode might offer some information about the m/z of the
unidentified compound.
4.6.5 Effects of C. perfringens on DZ
The effects of C. perfringens on DZ produced marked turbidity and a
concentration difference of -0.7 ± 2.7 ng/mL in sample 1 and -1.5 ± 1.0 ng/mL in sample
2. Results were summarized in Table 29 and Table 30.
Table 29 – Pre- and Post-Incubation Analysis: Effects of C. perfringens on Diazepam 1
Sample
Pre C. perfringens 1
Post C. perfringens 1
Δ Concentration

DZ
172.5 ± 1.5
171.9 ± 1.3
-0.7 ± 2.7

Concentration (ng/mL)
NDZ
OX
0.1 ± 0.0 0.0 ± 0.0
0.1 ± 0.0 0.0 ± 0.0
0.0 ± 0.0 0.0 ± 0.0
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TZ
0.0 ± 0.0
0.0 ± 0.0
0.0 ± 0.0

Table 30 – Pre- and Post-Incubation Analysis: Effects of C. perfringens on Diazepam 2
Sample
Pre C. perfringens 2
Post C. perfringens 2
Δ Concentration

DZ
184.9 ± 0.5
183.5 ± 0.5
-1.5 ± 1.0

Concentration (ng/mL)
NDZ
OX
0.1 ± 0.0 0.0 ± 0.0
0.1 ± 0.0 0.0 ± 0.0
0.0 ± 0.0 0.0 ± 0.0

TZ
0.0 ± 0.0
0.0 ± 0.0
0.0 ± 0.0

Similar to the studies performed on E. coli and B. fragilis, there were negligible
changes in concentration detected for NDZ, OX, and TZ. However, there was minimal
change in DZ concentration as well. These findings supported the theory that effects of
E. coli and B. fragilis resulted in the discrepancies between DZ analyte blanks and their
respective biotransformation studies.
The small change in DZ concentration, however, is unique. Disappearance of
DZ concentration similar to that seen in the analyte blanks was expected. However, this
was not observed in the DZ samples inoculated with C. perfringens. The concentration
difference between pre- and post-incubation was small enough that it could potentially
be explained by differences in instrumental response. Because DZ experienced this
uniquely minimal concentration loss, it is possible that introduction of C. perfringens or
perhaps a bacterial secretion somehow stabilized the analyte and prevented conversion
or degradation.
4.6.6 Effects of a Mixed Culture on DZ
The effects of joint incubation with E. coli, B. fragilis, and C. perfringens on DZ
produced turbid samples with a concentration difference of -1.1 ± 1.8 ng/mL in sample 1
and -4.8 ± 0.7 ng/mL in sample 2. Results were summarized in Table 31 and Table 32.

89

Table 31 – Pre- and Post-Incubation Analysis: Effects of Mixed Culture on Diazepam 1
Sample
Pre Mixed Culture 1
Post Mixed Culture 1
Δ Concentration

DZ
140.0 ± 0.7
138.8 ± 1.4
-1.1 ± 1.8

Concentration (ng/mL)
NDZ
OX
0.1 ± 0.0
0.0 ± 0.0
0.1 ± 0.0
0.0 ± 0.0
0.0 ± 0.0
0.0 ± 0.0

TZ
0.0 ± 0.0
0.0 ± 0.0
0.0 ± 0.0

Table 32 – Pre- and Post-Incubation Analysis: Effects of Mixed Culture on Diazepam 2
Sample
Pre Mixed Culture 2
Post Mixed Culture 2
Δ Concentration

Concentration (ng/mL)
DZ
NDZ
OX
159.3 ± 1.1 0.1 ± 0.0 0.0 ± 0.0
154.5 ± 1.5 0.1 ± 0.0 0.0 ± 0.0
-4.8 ± 0.7
0.0 ± 0.0 0.0 ± 0.0

TZ
0.0 ± 0.0
0.0 ± 0.0
0.0 ± 0.0

Samples were incubated with 100 µL each of E. coli and B. fragilis, and C.
perfringens. As seen with the C. perfringens samples, there was minimal change in DZ
concentration. This supported the supposition that the presence of C. perfringens
stabilized the analyte and prevented unassisted degradation as well as the proposed
conversions by E. coli and B. fragilis. As expected, there were negligible changes in
concentration detected for NDZ, OX, and TZ.

4.6.7 Flunitrazepam Blanks
Analysis of the FLU drug blanks exhibited a decrease in concentration of the
target analyte similar to that seen with DZ. FLU Drug Blank 1 (Table 33) produced an
average change in concentration of -25.9 ± 6.3 ng/mL and FLU Drug Blank 2 (Table 34)
an average difference of -40.2 ± 0.8 ng/mL. Unlike what was observed in the DZ blank
experiments, however, there was a corresponding increase in concentration for FLU
metabolites in the post-incubation samples. The 7AM metabolite exhibited increases in
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concentration of 15.7 ± 0.1 ng/mL (FLU Drug Blank 1) and 15.1 ± 0.2 ng/mL (FLU Drug
Blank 2).
Table 33 – Pre- and Post-Incubation Analysis: Flunitrazepam Drug Blank 1
Sample
Pre FLU Blank 1
Post FLU Blank 1
Δ Concentration Average

Concentration (ng/mL)
FLU
7AM
NDES
182.7 ± 5.3
0.1 ± 0.0
0.0 ± 0.0
156.8 ± 2.1
15.9 ± 0.1
0.0 ± 0.0
-25.9 ± 6.3
+15.7 ± 0.1 0.0 ± 0.0

Table 34 – Pre- and Post-Incubation Analysis: Flunitrazepam Drug Blank 2
Sample
Pre FLU Blank 2
Post FLU Blank 2
Δ Concentration Average

Concentration (ng/mL)
FLU
7AM
NDES
186.6 ± 3.7
0.2 ± 0.0
0.0 ± 0.0
146.4 ± 2.9 15.3 ± 0.2
0.0 ± 0.0
-40.2 ± 0.8 +15.1 ± 0.2 0.0 ± 0.0

FLU Drug Blank samples maintained sterility throughout the duration of the
experiments. Mass balance of the reaction indicated that approximately half of the
decrease in FLU concentration between pre- and post-incubation samples was
contributed to conversion to metabolite 7AM. This was most likely in response to the
incubation conditions and duration which led to an unassisted degradation. These
responses were supported by the processed sample stability study performed in the DZ
and FLU method validation (Section 3.3.8). In the stability study conducted for the 500
ng/mL sample, FLU demonstrated an average -54.1 ng/mL in concentration while 7AM
produced an average of +11.5 ng/mL from T=0 to T=48 hours. A visual representation
of pre- and post-incubation analyte concentrations was summarized in Figure 21.
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Figure 21 – Pre and Post-Incubation Concentrations of Flunitrazepam and Metabolites
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The remaining mass balance discrepancy, -8.3 ng/mL in sample 1 and -23.3
ng/mL in sample 2, between pre- and post-incubation FLU in the analyte blank
concentrations was otherwise unaccounted for. Mass balance for the reaction was
calculated by converting the original FLU concentration to moles and subtracting the
number of moles of 7AM produced. The remainder was reconverted back to grams of
FLU. This was the most accurate way to account for differences in mass between loss
of FLU and production of 7AM. NDES was absent in both pre- and post incubation
blanks. This suggested that FLU likely performed a partial, unassisted degradation to a
product other than the monitored metabolites.
92

4.6.8 Effects of E.coli on FLU
Analysis of the effects of E. coli on FLU concentration resulted in an average
concentration difference of –112.4 ± 2.6 ng/mL in sample 1 and -142.0 ± 3.3 ng/mL in
sample 2. These results were summarized in Tables 35 and Table 36, respectively.
Table 35 – Pre- and Post-Incubation Analysis: Effects of E. coli on Flunitrazepam 1
Sample
Pre E.coli 1
Post E.coli 1
Δ Concentration Average

Concentration (ng/mL)
FLU
7AM
NDES
142.0 ± 1.8
0.1 ± 0.0
0.0 ± 0.0
29.6 ± 0.9
93.5 ± 1.3
0.0 ± 0.0
-112.4 ± 2.6 +93.4 ± 1.3 0.0 ± 0.0

Table 36 – Pre- and Post-Incubation Analysis: Effects of E. coli on Flunitrazepam 2
Sample
Pre E.coli Blank 2
Post E.coli Blank 2
Δ Concentration Average

Concentration (ng/mL)
FLU
7AM
NDES
175.5 ± 3.6
0.2 ± 0.0
0.0 ± 0.0
33.4 ± 0.3
15.3 ± 0.6
0.0 ± 0.0
-142.0± 3.3 +93.7 ± 0.6 0.0 ± 0.0

As seen in the FLU drug blank samples, 7AM registered an increase in postincubation samples. However, the conversion of FLU to 7AM occurred to a greater
extent in samples inoculated with E. coli. Of the 112.4 ng/mL of FLU converted, an
average of 93.4 ng/mL was recovered in the form of 7AM in sample 1. Mass balance of
the reaction indicated that approximately 9.0 ng/mL of the original FLU concentration
was unaccounted for in sample 1 and 38.4 ng/mL in sample 2. Of the 142.0 ng/mL of
FLU converted in sample 2, only 93.7 ng/mL was converted to 7AM. The results can be
seen in Figure 22.

93

Figure 22 – Effects of E. coli on Pre and Post-Incubation Concentrations of
Flunitrazepam and Metabolites
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In the FLU drug blanks, 15.1-15.7 ng/mL of 7AM was recovered from the postincubation samples. This was similar to the conversion seen in sample 2. Both
samples demonstrated similar OD values and turbidity. This supported the theory that
FLU was being converted to an additional metabolite not monitored in this analysis.
There were several possible explanations for the discrepancies between FLU
disappearance and the appearance of 7AM. Based on the extent of FLU conversion, it
was evident that 7AM was the major metabolite produced by the biotransformation
conducted by E. coli in both samples. However, discrepancies in the mass balance of
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the reaction indicated that these bacterial species produced an alternative metabolite or
metabolites as well.
There were several possible explanations for the discrepancies between FLU
disappearance and the appearance of 7AM. 3-hydroxyflunitrazepam was a potential
candidate that should be included in future analysis and is depicted in Figure 23.
Figure 23 – Conversion of Flunitrazepam to 3-hydroxyflunitrazepam
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Additionally, Malanciuc et al. published a metabolism of FLU scheme that
included several additional compounds.58 These compounds were not included in this
research because 7-acetamino-flunitrazepam and 7-amino-nor-flunitrazepam are not
directly FLU metabolites. They are produced by the conversion of 7AM and can be
seen in Figure 24. Either of these were potential minor metabolites that would have
explained the slight concentration differences between the disappearance of FLU and
the production of 7AM.
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Figure 24 – Conversion of 7-Aminoflunitrazepam to 7-Acetamino-Flunitrazepam and 7Amino-Nor-Flunitrazepam
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As suggested with DZ, additional FLU and 7AM metabolites may account for the
discrepancies in mass balance of the reaction. Kinetic studies on the rate of
disappearance of FLU and rate of appearance of 7AM might also provide valuable
information that could aid in unidentified minor metabolite identification. Additionally,
analysis of the post-incubation sample via LC-MS/MS in full scan mode might offer
some information concerning the m/z of the unidentified compound.
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4.6.9 Effects of B. fragilis on FLU
Analysis of the effects of B. fragilis on FLU concentration produced turbid
samples and demonstrated an average concentration difference of -151.5 ± 2.7 ng/mL
in sample 1 and -117.9 ± 3.2 ng/mL in sample 2. In both instances, this represented
complete degradation of FLU. These results were summarized in Table 37 and Table
38, respectively.
Table 37 – Pre- and Post-Incubation Analysis: Effects of B. fragilis on Flunitrazepam 1
Sample
Pre B. fragilis 1
Post B. fragilis 1
Δ Concentration Average

Concentration (ng/mL)
FLU
7AM
NDES
151.5 ± 2.7
9.7 ± 0.1
0.0 ± 0.0
0.0 ± 0.0
129.3 ± 0.6 0.0 ± 0.0
-151.5 ± 2.7 +119.6 ± 0.7 0.0 ± 0.0

Table 38 – Pre- and Post-Incubation Analysis: Effects of B. fragilis on Flunitrazepam 2
Sample
Pre B. fragilis 2
Post B. fragilis 2
Δ Concentration Average

Concentration (ng/mL)
FLU
7AM
NDES
117.9 ± 3.2
8.6 ± 0.1
0.0 ± 0.0
0.0 ± 0.0
103.3 ± 0.9 0.0 ± 0.0
-117.9 ± 3.2 +94.8 ± 0.9 0.0 ± 0.0

In sample 1, the 7AM concentration increased by +119.6 ng/mL. Mass balance of
the reaction suggested that approximately 8.6 ng/mL of the original FLU was converted
to a compound other than those that were monitored in this method. Approximately 3.7
ng/mL of initial FLU was unaccounted for in sample 2. These effects can be seen in
Figure 25.
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Figure 25 – Effects of B. fragilis on Pre and Post-Incubation Concentrations of
Flunitrazepam and Metabolites
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4.6.10 Effects of C. perfringens on FLU
The effects of C. perfringens on FLU were similar to those produced by B.
fragilis. Incubation with C. perfringens resulted in complete reduction of FLU between
pre- and post-incubation samples for a total of -164.5 ± 4.7 ng/mL in sample 1 and 137.2 ± 2.1 ng/mL in sample 2. Results were summarized in Table 39 and Table 40.
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Table 39 – Pre- and Post-Incubation Analysis: Effects of C. perfringens on
Flunitrazepam 1
Sample
Pre C. perfringens 1
Post C. perfringens 1
Δ Concentration Average

Concentration (ng/mL)
FLU
7AM
NDES
164.5 ± 4.7
0.1 ± 0.0
0.0 ± 0.0
0.0 ± 0.0
134.0 ± 0.9 0.0 ± 0.0
-164.5 ± 4.7
+133.8 ± 0.9 0.0 ± 0.0

Table 40 – Pre- and Post-Incubation Analysis: Effects of C. perfringens on
Flunitrazepam 2
Sample
Pre C. perfringens 2
Post C. perfringens 2
Δ Concentration Average

Concentration (ng/mL)
FLU
7AM
NDES
137.2 ± 2.1
0.1 ± 0.0
0.0 ± 0.0
0.0 ± 0.0
124.0 ± 0.7 0.0 ± 0.0
-137.2 ± 2.1 +123.9 ± 0.7 0.0 0.0

In sample 1, the 7AM concentration increased by +133.8 ng/mL. Mass balance
of the reaction suggested that approximately 16.4 ng/mL of FLU was converted to an
alternative compound or metabolite. In sample 2, only 0.1 ng/mL of the original FLU
concentration was unrecovered. These effects were depicted in Figure 26. The
potential minor metabolites proposed for E. coli and B. fragilis biotransformations were
also candidates with C. perfringens inoculates, however, further investigations would be
required before a definitive identification could be provided.
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Figure 26 – Effects of C. perfringens on Pre and Post-Incubation Concentrations of
Flunitrazepam and Metabolites
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4.6.11 Effects of a Mixed Culture on FLU
The effects of the mixed culture reduced the initial FLU concentrations by -103.3
± 2.6 ng/mL in sample 1 and -149.6 ± 2.0 ng/mL in sample 2, both of which represented
complete conversions. Results were summarized in Tables 41 and 42.
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Table 41 – Pre- and Post-Incubation Analysis: Effects of Mixed Culture on
Flunitrazepam 1

Sample
Pre Mixed Culture 1
Post Mixed Culture 1
Δ Concentration Average

Concentration (ng/mL)
FLU
7AM
NDES
103.3 ± 2.6
3.5 ± 0.1
0.0 ± 0.0
0.0 ± 0.0
86.9 ± 1.2
0.0 ± 0.0
-103.3 ± 2.6 +83.4 ± 1.2 0.0 ± 0.0

Table 42 – Pre- and Post-Incubation Analysis: Effects of C. perfringens on
Flunitrazepam 2
Sample
Pre Mixed Culture 2
Post Mixed Culture 2
Δ Concentration Average

Concentration (ng/mL)
FLU
7AM
NDES
150.9 ± 2.9
3.9 ± 0.0
0.0 ± 0.0
0.0 ± 0.0
123.7 ± 0.0 0.0 ± 0.0
-149.6± 2.0 +119.9± 0.0 0.0 ± 0.0

FLU demonstrated concentration loss for each bacterial species individually as
well as the mixture of bacteria. Mixed culture samples produced the complete
transformation of FLU as seen with B. fragilis and C. perfringens. Mass balance of the
reaction demonstrated that approximately 7.2 ng/mL of FLU in sample 1 and 14.1
ng/mL in sample 2 was not recovered in the form of 7AM. Data are depicted in Figure
27. As with the other cultures, data suggested that an alternative metabolite or multiple
metabolites were likely being produced. However, the identity of these structures will
require further experiments and analysis.
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Figure 27 – Effects of Mixed Culture on Pre and Post-Incubation Concentrations of
Flunitrazepam and Metabolites
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The data exhibited by the effects of E. coli, B. fragilis, C. perfringens, and mixed
culture was consistent with that published by Robert and Drummer, detailed in section
1.1.3.16 In this study, Robertson and Drummer studied effects of 8 GI bacteria on
clonazepam, flunitrazepam, and nitrazepam in blood. They found that all three
compounds were converted to their respective 7-amino metabolites, though the rate of
conversion varied amongst the different species. However, analysis was limited by their
methodology. The experimental run time was 25 minutes whereas the previously
validated LC-MS/MS method was 8 minutes. LOQ values for their analytes were all 10
ng/mL. LOQ values for the presented methods ranged from 0.1-1.0 ng/mL with DZ and
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FLU at 0.5 and 7AM at 0.1 ng/mL. In addition, they did not prepare analyte blanks for
analysis. As seen in this research, DZ and FLU both underwent a partial, unassisted
degradation when incubation under experimental conditions and duration. These
authors also performed temperature studies to study the effect of temperature on
conversion rate of FLU to 7AM. This would be an interesting inclusion in future works.

4.7.0 Conclusions
An LC-MS/MS method was previously validated for the simultaneous detection,
identification, and quantitation of the benzodiazepines DZ, FLU, and their respective
metabolites which were recovered from RCM using SPE (Chapter 3). The method was
applied to experimental explorations involving bacterial biotransformation of the drugs of
abuse DZ and FLU.
Pre- and post-incubation aliquots were extracted and analyzed via LC-MS/MS.
Analytes and metabolites were evaluated for acceptable peak shape, retention time, ion
ratios, and S/N ≥ 3 for detection as well as bias and precision within ±20% for
quantitation. A series of blanks was prepared in RCM and incubated alongside samples
inoculated with bacteria.
Analysis and mass balance of the DZ blank suggested the analyte must undergo
a partial, unassisted degradation when incubated at 37°C for 48 hours. However, NDZ,
OX, nor TZ registered an increase from pre- to post-incubation concentrations. The DZ
degradation product was therefore unidentified. Analysis of the FLU drug blanks
likewise exhibited a decrease in concentration; however, there was a corresponding
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increase in concentration in 7AM metabolites in the post-incubation samples that
accounted for some of the FLU loss.
Analysis of the effects of E. coli and B. fragilis on DZ concentration demonstrated
an average concentration difference greater than that seen in the blanks. In
accordance with drug blank samples, neither NDZ, OX, nor TZ registered a detectible or
quantifiable increase from pre- to post-incubation concentrations. The discrepancies
between blank and biotransformation study samples indicated that there may be
additional factors contributing to the transformation of DZ when incubated with E.coli or
B. fragilis. A possible explanation was that DZ was being converted to a compound
other than the human metabolites NDZ, OX, and TZ monitored. In this case, E. coli and
B. fragilis possessed a specific enzyme or combination of enzymes that were capable of
cleaving DZ to form some type of alternative metabolite. Additional experimental and
literature review may offer some guidance.
There were negligible changes in concentration detected for NDZ, OX, and TZ in
samples inoculated with C. perfringens. However, there was minimal change in DZ
concentration as well. These findings supported the theory of E. coli and B. fragilis
were responsible for the concentration discrepancies between the DZ drug blanks and
their respective biotransformation studies. The small change in DZ concentration,
however, was unique. The difference was small enough that it could potentially be
explained by differences in instrumental response. However, the C. perfringens
samples were incubated alongside the other blanks and inoculates, and loss of DZ
concentration similar to that seen in the drug blank samples was expected. Since DZ
experienced minimal concentration loss, it is possible that introduction of C. perfringens
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stabilized the analyte and prevented degradation. The effects of mixed culture resulted
in similar responses to those seen in C. perfringens. This supported the supposition
that the presence of C. perfringens stabilized the analyte and prevented the proposed
degradation by E. coli and B. fragilis.
E. coli, B. fragilis, C. perfringens, and a mixture of the three species were all
capable of transforming FLU to 7AM to varying extents in RCM. E. coli converted the
majority of FLU but was not as efficient as the anaerobic species. 7AM exhibited an
increase in concentration between pre- and post-incubation samples which accounted
for some of the FLU loss. However, not all of the original FLU concentration was
recovered as 7AM as evidenced by mass balance of the reaction. This could have
been attributed to transformation of FLU into an additional metabolite that was not
monitored such as 3-hydroxyflunitrazepam. Another possibility was conversion of 7AM
to 7-acetamino-flunitrazepam and/or 7-amino-nor-flunitrazepam. However, further
analysis would be required to determine the presence and identity of these or other
potentially unique bacterial metabolites.
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Chapter 5 – A Validated Method for the Quantitation of
Cocaine, Fentanyl, and Metabolites in Reinforced Clostridial
Medium by Liquid Chromatography-Tandem Mass
Spectrometry
5.1.0 Introduction
In Chapter 3, a method was developed and validated for the quantitation of DZ
and FLU in RCM. This chapter focused on expanding the previous methodology to
investigate other analytes of interest.
A novel LC-MS/MS method was developed and validated for simultaneous
analysis and quantitation of cocaine (COC) and metabolites anhydroecgonine methyl
ester (AEME), benzoylecgonine (BZE), cocaethylene (CE), ecgonine methyl ester
(EME), m-hydroxycocaine (mHC), and norcocaine (NC) as well as fentanyl (FENT), and
metabolites norfentanyl (NF), and despropionyl fentanyl (DESP) in RCM. RCM is a
bacterial nutrient medium, the components of which were discussed in Table 2.
COC and FENT are classified by the DEA as Schedule II drugs of abuse.24 They
were selected as the target analytes due to the importance in analytical and forensic
toxicology. Human metabolic studies have been well documented and the analyte and
metabolite standards were commercially available.
According to the Substance Abuse and Mental Health Services Administration
(SAMHSA) - National Survey on Drug Use and Health there were approximately 1.1
million COC users in the United States in 2012.64 COC is most commonly snorted,
smoked, or injected, and acts as a CNS stimulant. It is considered to be highly
addictive compound and is linked to adverse health effects including increase in blood
pressure, body temperature, and heart rate, as well as feelings of panic and paranoia.
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COC has been known to cause cardiovascular complications, seizures, and stroke in
users as well. Human metabolism of COC has been extensively studied, and many
metabolites have been identified. Only the first generation metabolites of AEME, BZE,
CE, EME, mHC, and NC were investigated for the purposes of this research. The
metabolism scheme for COC is displayed in Figure 28.50,51,65-82 6568,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81

Figure 28 – Human Metabolites of Cocaine
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FENT is a synthetic opiod analgesic. It is classified as both a drug for medicinal
purposes and a drug of abuse. For medical purposes, it is known as Actiq®,
Duragesic®, and Sublimaze®.24, 64, 82 It is most often used in various forms of pain
management. This drug is commonly administered as an injection, but can also be
seen in transdermal patches as well as lozenges. It binds to opiate receptors in the
body and causes nausea, sedation, respiratory depression, respiratory arrest, and
coma.24, 64, 82 Human metabolites include NFENT and DESP. The metabolism scheme
for FENT is displayed in Figure 29.51,84-8851
, 83,84,85,86,87

Figure 29 – Human Metabolites of Fentanyl
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5.2.0 Materials and Methods
5.2.1 Materials
Analyte reference standards for COC, AEME, BZE, CE, EME, NC, FENT, and
NFENT as 1.0 mg/mL, and cocaine-d3 (COC-d3), benzoylecgonine-d3 (BZE-d3),
cocaethylene-d3 (CE-d3), ecgonine methyl ester-d3 (EME-d3), norcocaine-d3 (NC-d3),
fentanyl-d5 (FENT-d5), and norfentanyl-d5 (NFENT-d5) as 100 µg/mL were purchased
from Cerilliant® (Round Rock, TX). The m-hydroxycocaine (mHC) was purchased as a
1.0 mg solid from Sigma-Aldrich ® (St. Louis, MO) and despropionyl-3-methylfentanyl
(despropionyl fentanyl) (DESP) was purchased as a 1.0 mg solid from Enzo ® Life
Sciences (Farmingdale, NY). Both of these standards were dissolved in 1 mL of MeOH
for working standard and dilution preparations.
Ammonium acetate, ammonium hydroxide (NH4OH), FA eluent additive for LCMS, hydrochloric acid (HCl), and LC-MS CHROMASOLV® ACN and MeOH were
purchased from Sigma-Aldrich®. The IPA (Optima™ LC/MS) was purchased from
Fischer Scientific and HPLC grade EA from JT Baker® (Center Valley, PA). Strata™-XDrug B Strong Cation Mixed Mode 60mg/3mL cartridges were obtained from
Phenomenex® (Torrance, CA). The narrow bore ZORBAX Eclipse XDB-C8 (2.1 mm x
150 mm x 5 µm) column affixed with a ZORBAX Eclipse XDB-C8 (2.1 mm x 12.5 mm x
5 µm) guard cartridge were obtained from Agilent Technologies (Santa Clara, CA).
RCM was obtained from BD Difco™ (Sparks, MD).
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5.2.2 Sample Preparation
An initial calibration curve was prepared from working solutions in buffer and
plotted at 0.05, 0.1, 0.25, 0.5, 1, 5, 10, 25, 50, 100, and 200 ng/mL. Calibration curves
for each analyte in buffer can be seen in Appendix D. Three different SPE methods
were evaluated for recovery of COC, FENT, and metabolites. Reagents and solvents
consisted of acetonitrile (ACN), ethyl acetate (EA), isopropyl alcohol (IPA), formic acid
(FA), methanol (MeOH), and ammonium hydroxide (NH4OH). Details of the methods
are shown in Figure 30 and Figure 31.
Figure 30 – SPE 1 and SPE 2 for Cocaine, Fentanyl and Metabolites
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•0.1% FA
•MeOH/H2O (30/70 v/v)
•10 minutes
•2% NH4OH in
ACN/MeOH (1/1 v/v)

Figure 31 – SPE 3 for Cocaine, Fentanyl and Metabolites
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Three working solutions containing all ten analytes at 10,000 ng/mL (WS1), 1000
ng/mL (WS2), and 10 ng/mL (WS3) in water/acetonitrile:methanol (80/20 v/v) were used
to prepare the dilution sets required in the method validation studies. An internal
standard working solution consisting of the seven deuterated standard compounds was
prepared at 2500 ng/mL. The RCM matrix was composed of ten 100 mL aliquots of
RCM (3.8 g RCM in 100 mL of DI water) which were prepared, pooled, and then
autoclaved at 121°C for 15 minutes.
All samples were spiked with 200 µL of 0.1N HCl to ensure pH between 4.0 and
6.0 which was necessary for extraction. SPE was used to isolate target analytes from
media components. Extractions were performed at 3 concentrations spanning the
concentration range. After analysis, SPE 1 was chosen for this method.
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The Strata™-X-Drug B cartridges are based on a polymeric strong-cation mixed
mode sorbent specifically designed for basic drugs of abuse. These cartridges and
SPE 1 method were chosen because they demonstrated the greatest responses for the
analytes of interest and metabolites across the three concentrations. The cartridges did
not require conditioning steps which was advantageous because SPE required less
time and solvent per sample. This also reduced the amount of hazardous waste
produced as well.
Samples (1 mL) were directly loaded onto the Strata™-X-Drug B cartridges (no
conditioning) and washed with 1 mL of 0.1N HCl. Wash 1 was designed to minimize
salt content and other polar compounds that could interfere with instrumental analysis.
Cartridges were also washed with 1 mL of MeOH (Wash 2) to minimize the nonpolar
matrix constituents, and then dried under full vacuum for 10 minutes. Samples were
eluted with 1 mL of a freshly prepared mixture of EA:IPA:NH4OH (70:20:10 v/v/v), dried
under nitrogen, and reconstituted in water/acetonitrile:methanol (80/20 v/v).
.

5.2.3 Instrumental Analysis
Method development and analysis were performed using LC-MS/MS.
Instrumentation was the same used to develop and validate the DZ and FLU method in
Chapter 3. Samples (2 µL) were injected at a flow rate of 0.250 mL/min. The buffer
system consisted of 20 mM ammonium acetate adjusted to pH 2.7 with FA (A) and
acetonitrile/methanol (50/50 v/v) (B). Analytes were separated using a gradient elution
program of 20% B for 2 minutes, to 45% B over 10.5 minutes, back to original
conditions over 0.1 minute, and then column equilibration for 1.4 minutes. Total run
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time was 14 minutes followed by a 2 minute post-run at 20% B to ensure stable column
conditions before the next injection.
The AJS ESI source was operated in the positive mode and parameters were
optimized using Source and iFunnel Optimizer with a 100 ng/mL sample containing all
of the target analytes, metabolites, and standards. The gas temperature was optimized
at (265°C), gas flow (19 L/min), nebulizer (50 psi), sheath gas temperature (350°C),
sheath gas flow (11 L/min), capillary (3250 V), ΔEMV (200), fragmentor (380 V), and
cell acceleration (2 V). The column was maintained at 37°C and the autosampler at
4°C.
MassHunter™ Optimizer software was used to determine the best MRM
transitions for each analyte of interest as well as their corresponding deuterated
standards. The software provided up to four ion transitions for each analyte, the results
for which can be seen in Appendix E. All of the suggested ions were included in the
initial calibration. The two ion transitions that demonstrated the greatest signal
response while also maintaining stable ion ratios across the calibration range were
selected as the quantifier and qualifier ions for each analyte.
MRM data were only acquired in a narrow window based upon the RT of the
analyte of interest. Because some of the ions had similar ion transitions, the narrow
range of acquisition increased the selectivity for each individual analytes. Samples
were quantified by comparing the peak area response ratio of the target analyte to that
of the corresponding deuterated standard. RT, quantifier and (qualifier) ion transitions,
CE, ion ratios, and deuterated standard selection for each analyte is summarized in
Table 43.
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Table 43 – LC-MS/MS Parameters for Cocaine, Fentanyl, and Respective Metabolites
in RCM

Analyte
COC

RT
(mins)
9.0

Q1
(m/z)
304.2

Q3
(m/z)
182.0
(150.0)
185.0

CE
(V)
13
20
15

Ion
Ratio
8.7

ISTD
COC-d3

COC-d3

9.0

307.2

AEME

2.05

182.1

118.0
(122.1)

25
17

72.0

EME-d3

BZE

6.0

290.1

BZE-d3

6.0

293.1

13
20
13

35.8

BZE-d3

168.0
(104.9)
171.0

CE

11.2

318.2

CE-d3

11.2

321.2

13
20
13

9.4

CE-d3

196
(150.0)
199.0

EME

1.6

200.1

EME-d3

1.6

203.1

29
20
13

10.5

EME-d3

82.1
(150.0)
(185.0)

mHC

5.65

320.2

182.0
(82.0)

13
20

19.9

BZE-d3

NC

9.7

290.1

NC-d3

9.7

293.1

9
17
9

64.8

NC-d3

168.0
(136.0)
171.0

FENT

13.2

337.2

FENT-d5

13.2

342.3

45
21
19

84.5

FENT-d5

(105.0)
(188.1)
188.0

NFENT

7.0

233.2

NFENT

7.0

238.0

15
31
15

4.2

NFENTd5

84.0
(93.9)
84.0

DESP

12.5

281.2

105.0
(188.0)

31
15

73

FENT-d5
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The separation and MRM transitions of the analytes can be seen in the
chromatogram in Figure 32. The purpose of chromatographic separation in this method
was to minimize the co-elution of target analytes and their respective metabolites.
These compounds were similar in structure and many utilized the same ion transitions,
which can lead to ionization effects that affect quantitation. Maximizing analyte
separation and limiting MRM data acquisition to the narrow window incorporating
analyte retention time enhanced the selectivity for each individual analytes.
Figure 32 – MRM of Cocaine, Fentanyl, and Respective Metabolites in RCM
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Unlike the DZ and FLU method developed in Chapter 3, deuterated standards
were not available for all of the metabolites of interest. Internal standards for these
compounds were selected based upon compounds with similar structure as well as RT,
a feature of analyte response to the column, buffer system, and elution gradient.
5.2.4 Method Validation
Method validation definitions and parameters were detailed in Chapter 1. The
presented method was fully validated and included a calibration model, interference
studies, carryover effects, ionization suppression and enhancement, ME, RE, PE, bias
and precision, LOD, LOQ, dilution integrity, and processed sample stability.
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5.3.0 Results and Discussion
5.3.1 Calibration Model
Calibration and QC standards were prepared in media using WS1, WS2, and
WS3, and the internal standard working solution. Final calibrations were based on a 10point model of 0.1, 0.25, 0.5, 1, 5, 10, 25, 50, 100, and 200 ng/mL for the analytes and
25 ng/mL for the corresponding deuterated standards. Calibrations were determined
using a linear model excluding the origin and with 1/x weighting. Correlation coefficients
were >0.99 (n=5) for all analytes of interest in RCM, and can be seen in Appendix F.
Calibration range, slope, y-intercept, R2, LOD, and LOQ values are summarized in
Table 44.
Table 44 – Calibration Curve Data, LOD, and LOQ for Cocaine, Fentanyl, and
Respective Metabolites in RCM
Analyte
COC
AEME
BZE
CE
EME
mHC
NC
FENT
NFENT
DESP

Calibration Range
(ng/mL)
0.1 - 200
10 - 200
0.1 - 200
0.25 - 200
5 - 200
0.25 - 200
0.25 - 200
0.25 - 200
0.5 - 200
0.25 - 200

Slope
(x10-2)
4.11
1.31
4.49
4.53
1.73
1.09
3.87
5.70
8.34
5.85

Y-Intercept
(x10-3)
-5.71
5.29
-0.356
-2.71
11.8
-4.90
1.09
3.43
-19.2
-1.24

R2
0.999
0.995
0.997
0.996
0.992
0.995
0.996
0.995
0.997
0.993

LOD
(ng/mL)
0.1
10
0.1
0.25
5.0
0.1
0.1
0.1
0.5
0.1

LOQ
(ng/mL)
0.1
10
0.1
0.25
5.0
0.25
0.25
0.25
0.5
0.25

5.3.2 Interference Studies
Ten RCM samples were prepared, pooled, and then autoclaved for interference
and other validation studies. Blank matrix samples were extracted and then analyzed
via LC-MS/MS to determine possible interferences with the analytes of interest based
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upon retention time, peak shape, and ion ratio. Some of the analyte responses were
indicative of matrix effects, however all of the responses failed to satisfy analyte
identification criteria of RT, peak shape, and ion ratios. Extent of matrix effects were
examined in greater detail using the Matuszewski methods in Section 5.3.4.28
Deuterated standard blanks at 25 ng/mL were also examined for possible
interferences that could be caused by impurities or similar fragmentation patterns of
analyte and internal standards. Interferences were negligible based upon the previously
established identification criteria.
5.3.3 Carryover Analysis
To determine carryover effects, samples were prepared at the two highest
calibration points, 100 and 200 ng/mL, as well as two higher concentrations of 300 and
400 ng/mL. Each sample injection was followed by an extracted blank sample injection.
Analyte carryover was detected at all four concentrations. To minimize or eliminate
these effects, blank samples were injected between each sample analysis.
5.3.4 Ionization Suppression/Enhancement and Recovery
ME, RE, and PE were all calculated using the Matuszewski equations and
methods which are defined in Section 1.5.3. Three sets of samples were prepared at
three concentrations to span the range of LOD and LOQ values of the analytes of
interest.28 Results were summarized in Table 45 and Table 46.
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Table 45 – Matrix Effects, Recovery, and Process Efficiency for Cocaine and
Metabolites in RCM
Analyte

ME (%)
RE (%)
PE (%)

ME (%)
RE (%)
PE (%)

ME (%)
RE (%)
PE (%)

ME (%)
RE (%)
PE (%)

COC

AEME

BZE

EME

mHC

NC

103.0
97.7
100.6

49.4
136.1
67.2

High (200 ng/mL)
107.1
87.9
87.5
97.6
97.9
98.9
104.5
86.0
86.5

104.7
105.7
110.6

96.7
98.2
94.9

95.6
94.0
89.9

Medium/High (25 ng/mL)
70.2
98.1
97.1
100.8
225.4
94.4
94.3
99.6
158.2
92.7
91.6
100.4

142.7
94.3
134.7

98.3
94.0
92.4

14.7
73.8
10.9

Medium/Low (5 ng/mL)
106.2 100.8
91.7
101.8
98.9
105.4
108.1
99.7
96.7

256.8
109.2
290.4

102.4
100.2
102.6

-

Low (0.5 ng/mL)
88.0
81.0
95.0
94.8
83.6
76.7
-

144.7
100.3
145.1

85.3
92.8
79.2

94.9
99.5
94.4

79.5
92.8
73.8
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CE

Table 46 – Matrix Effects, Recovery, and Process Efficiency for Fentanyl and
Metabolites in RCM
Analyte

FENT

NFENT

DESP

ME (%)
RE (%)
PE (%)

High (200 ng/mL)
88.0
93.9
93.6
98.8
99.7
98.7
86.9
93.7
92.4

ME (%)
RE (%)
PE (%)

Medium/High (25 ng/mL)
96.9
97.7
97.7
94.9
94.5
96.0
92.0
92.3
93.8

ME (%)
RE (%)
PE (%)

Medium/Low (5 ng/mL)
102.9
103.1
106.0
99.9
100.6
98.3
102.8
103.7
104.3

ME (%)
RE (%)
PE (%)

Low
88.4
95.6
84.5

(0.5 ng/mL)
81.0
85.8
95.0
94.8
76.9
81.3

The ME, RE, and PE reflect the ability and efficiency of the SPE method. Matrix
effects showed slight ionization enhancement for COC, BZE, and mHC at high
concentration. The other analytes experienced ionization suppression with ME ranging
from 87.5% to 96.7%. RCM is a complex medium and both ionization enhancement as
well as suppression effects can be contributed to matrix components.
AEME experienced matrix effects of 49.4% even at high concentration. This
apparent suppression was a result of several factors. There was no deuterated AEME
standard in this method, and using EME-d3 may not have been adequate for accurate
quantitation. Additionally, AEME was a very polar molecule and eluted near the solvent
front. This could cause ionization to be incomplete as well as inconsistent. Finally,
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AEME eluted soon after EME and their MRM transition peaks exhibited some tailing.
These two molecules differed only by a water molecule and the most abundant
transition of EME was the 182.0 m/z of AEME. This transition was not selected to be
monitored for EME, but with the analytes eluting so close together, the RT window could
not be narrowed enough to isolated the analyses. All of these factors could explain the
method effects on AEME individually, but most likely a combination of effects was
responsible. The RE and PE of AEME were also affected across all concentration
levels. Analysis of AEME will be very limited in this method.
ME were more prominent for the other analytes at low concentration with
suppression ranging from 79.5 to 85.8%. mHC is the only analyte at low concentrations
to express ionization enhancement at 144.7%. This could be attributed to the lack of
deuterated mHC. BZE may not have accurately defined the responses of mHC at lower
concentrations which resulted in increased ionization enhancement. It could also be
attributed to matrix components that interfered with mHC ionization and signal
response.
Recovery ranged from 92.8 to 109.2% across all concentration levels for both
sets of analytes and metabolites (except AEME). This indicated that the SPE method
was efficient in retrieving analytes from the matrix. However, the method was not as
successful in removing matrix components as evidenced by the extent of ME on all
analytes. Perhaps an additional wash step or maybe a syringe filtering could be applied
to improve the clean up. The RE % was not calculated for EME at 0.5 ng/mL because it
was below the LOQ.

120

PE was designed to take ionization effects as well as recovery into account. PE
ranged from 86.0 to 110.6% for high and medium concentration levels for COC, BE, CE,
NC, FENT, NFENT, and DESP, and 73.8 to 84.5% at low concentration. PE ranged
from 110.6 to 290.4% for mHC while recoveries only ranged from 94.3-109.2% across
all concentrations. The high PE values are therefore due to matrix effects. Over all, the
FENT and metabolites were much less affected by ME than COC and metabolites.
FENT analytes also had significantly better recoveries across all concentration levels.
5.3.5 Bias and Precision
Bias and precision (within-run precision) and repeatability (between-run
precision) were defined in Chapter 1. The values were calculated using Equation 4,
Equation 5, and Equation 6, respectively. Analysis of percent bias and within-run and
between-run precision was conducted at four different concentrations 100 (high), 10
(medium/high), 5 (medium/low), and 0.5 ng/mL (low) for COC, BZE, CE, mHC, NC,
FENT, NFENT, and DESP. EME studies were conducted only at the high,
medium/high, and medium/low concentrations, and AEME only at the high and
medium/high concentrations due to LOD and LOQ limitations. Data is summarized in
Table 47 and Table 48.
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Table 47 – Bias, Within-Run and Between-Run %CV for Cocaine and Metabolites in
RCM
Analyte

Bias (%)
Within-Run (%)
Between-Run (%)

Bias (%)
Within-Run (%)
Between-Run (%)

Bias (%)
Within-Run (%)
Between-Run (%)

Bias (%)
Within-Run (%)
Between-Run (%)

COC

AEME

BZE

CE

EME

mHC

NC

High (100 ng/mL)
-7.4
-8.3
-11.0
2.1
1.7
1.2
4.5
3.5
3.8

-7.7
2.2
6.8

-9.6
7.1
7.3

-13.2
3.2
4.3

-9.9
2.5
5.8

-8.2
2.0
10.1

Medium/High (10 ng/mL)
3.1
-8.6
-5.7
-5.8
-11.4
3.4
2.7
1.8
1.6
2.2
12.2
10.9
9.8
12.8
11.3

10.3
1.6
9.9

-5.2
1.7
7.9

-

Medium/Low (5 ng/mL)
-3.6
-12.7 -16.0
3.0
1.8
1.0
4.5
8.1
4.1

-19.6
2.2
3.9

-9.0
6.0
11.0

-

Low (0.5 ng/mL)
-5.0
-18.4
7.2
7.8
6.5
5.3
-

-15.8
7.2
7.0

-11.1
7.0
5.4

-17.4
4.4
4.8
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Table 48 – Bias, Within-Run and Between-Run %CV for Fentanyl and Metabolites in
RCM
Analyte

FENT

NFENT

DESP

Bias (%)
Within-Run (%)
Between-Run (%)

High (100 ng/mL)
-11.6
-6.5
-11.5
1.1
1.4
2.1
3.3
4.3
3.6

Bias (%)
Within-Run (%)
Between-Run (%)

Medium/High (10 ng/mL)
-10.4
-7.1
-9.7
2.2
1.5
1.1
11.9
9.5
13.8

Bias (%)
Within-Run (%)
Between-Run (%)

Medium/Low (5 ng/mL)
-19.0
-5.8
-15.2
2.5
1.9
1.1
8.1
8.2
7.2

Bias (%)
Within-Run (%)
Between-Run (%)

Low (0.5 ng/mL)
-11.3
-18.8
-15.0
6.1
5.3
5.8
7.0
7.2
6.7

Within-run precision ranged from 1.1 to 7.8% across each of the concentration
levels while between-run precision ranged from 3.3 to 13.8%. For most analytes the
higher concentration sample sets demonstrated the narrowest range of values.
Generally, bias and precision values increased as concentration values decreased
toward the LOD and LOQ values of the analytes. Even though the acceptable range is
±20% is the same for all concentration levels, small changes in sample extraction and
preparation as well as instrumental response have a greater effect on lower
concentrations than higher concentrations. This trend was also seen with DZ, FLU, and
their metabolites.
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5.3.6 Dilution Integrity
Dilution integrity was determined by repeating bias and precision studies on
diluted samples. Samples were prepared at 1000 ng/mL and then diluted to 1:5 (200
ng/mL) and 1:10 (100 ng/mL). Five samples were prepared and analyzed in triplicate
for each concentration. Both dilution sets maintained requisite identification criteria for
all analytes except for AEME. Excluding AEME, the bias ranged from -10.6 to 14.0%,
within-run precision from 0.7 to 2.0%, and between-run precision from 1.7 to 7.4%. The
bias for AEME in the 1:10 dilution set was higher than ±20%. Future dilutions should be
prepared at 1:5. The summarized data can be seen in Table 49 and Table 50.

Table 49 – Dilution Integrity for Cocaine and Metabolites in RCM
Analyte

Bias (%)
Within-Run (%)
Between-Run (%)

Bias (%)
Within-Run (%)
Between-Run (%)

COC

AEME

EME

mHC

NC

-3.5
0.7
4.3

1:5 (1000:200 ng/mL)
-19.8
-5.9
5.5
2.7
1.2
1.4
1.3
1.2
7.4
4.7
4.7
4.4

14.0
1.5
5.4

1.2
1.3
4.6

-4.9
1.5
2.6

1:10 (1000:100 ng/mL)
-25.3
-9.0
4.1
-1.0
1.3
1.4
1.3
2.0
3.4
2.6
2.7
2.7

9.8
1.6
1.7

-1.0
1.2
2.4
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BZE

CE

Table 50 – Dilution Integrity for Cocaine, Fentanyl, and in RCM
Analyte

FENT

NFENT

DESP

Bias (%)
Within-Run (%)
Between-Run (%)

1:5 (1000:200 ng/mL)
-1.0
9.0
-7.5
1.6
1.5
1.2
4.4
5.2
4.7

Bias (%)
Within-Run (%)
Between-Run (%)

1:10 (1000:100 ng/mL)
-4.1
5.4
-10.6
1.5
1.5
1.1
2.8
2.4
2.7

5.3.7 LOD and LOQ
LOD and LOQ were defined in Sections 1.5.7 and 1.5.8, respectively. Values for
COC, FENT, and metabolites ranged from 0.100 to 10 ng/mL and are reported in Table
2. COC and BZE achieved the lowest LOD and LOQ values at 0.1 ng/mL. mHC, NC,
FENT, and DESP maintained RT, peak shape, and ion ratios at 0.1 ng/mL, satisfying
LOD requirements but bias exceeded ± 20%. The LOQ requirements were fulfilled at
0.25 ng/mL for these analytes. All of the analytes of interest had LOQ values ≤ 0.5
ng/mL with the exceptions of AEME and EME. Both of these analytes eluted near or
possibly with the solvent front. This caused ionization to be incomplete as well as
inconsistent, which resulted in higher LOD and LOQ values. The lack of a deuterated
AEME standard also affected quantitation at lower concentrations.
5.3.8 Stability
Stability was assessed by evaluating freeze-thaw stability as well as processed
sample stability., which were defined in Section 1.5.11. Freeze-thaw stability was
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conducted over three cycles at three concentrations 200 ng/mL (high), 10 ng/mL
(medium), and 0.5 ng/mL (low).
COC, BZE, CE, NC, and NFENT remained stable for all three concentrations and
FT cycles. EME was stable for all three cycles at the high and medium concentrations,
however the low concentration sample was below the LOQ of EME. Fentanyl was
stable for FT1, FT2, and FT3 for high concentration, and FT1 and FT2 for medium
concentration. All concentrations were stable for FT1 and FT2 for mHC and DESP.
With the exception of AEME, most analytes should remain stable through two complete
freeze-thaw cycles at high and medium concentrations. Experimental values for AEME
were well above the theoretical values for all concentrations and cycles. Future
analyses involving quantitation of AEME should therefore be conducted immediately
after preparation and not preserved by freezing.
The stability of processed samples was studied at two concentrations 200 ng/mL
(high) and 5 ng/mL (low) in triplicate over the course of 60 hours. Samples were taken
every 12 hours to accommodate the sample run time. For 200 ng/mL, cocaine and
metabolites remained stable until the 48 hour mark. At 60 hours, however, mHC
dropped below the 160-240 (±20%) ng/mL range (dashed lines). Error bars were
determined at the 95% confidence interval. This was depicted in Figure 33. Fentanyl
and metabolites remained stable for the entirety of the 60 hour stability testing as seen
in Figure 34.
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Figure 33 – Processed Sample Stability for Cocaine and Metabolites in RCM at High Concentration (200 ng/mL)
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Figure 34 – Processed Sample Stability for Fentanyl and Metabolites in RCM at High Concentration (200 ng/mL)
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At low concentration (5 ng/mL), COC and metabolites remained stable for at
least 60 hours (Figure 35) as did FENT and metabolites (Figure 36). Error bars were
determined at the 95% confidence interval, and dashed lines represent the ±20% range.
The stability of AEME was not assessed at the low concentration because it was below
the LOQ for that particular metabolite. Based on these studies, samples should remain
stable for at least 48 hours. This was an important feature of method validation,
especially in cases of large sample batches as well as periods of instrumental
malfunction.
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Figure 35 – Processed Sample Stability for Cocaine and Metabolites in RCM at Low Concentration (5 ng/mL)
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Figure 36 – Processed Sample Stability for Fentanyl and Metabolites in RCM at Low Concentration (5 ng/mL)
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5.4.0 Conclusions
An LC-MS/MS method was developed and validated for the detection,
identification, and quantitation of COC, FENT, and metabolites extracted from RCM.
This method can be used to apply the analyte degradation and biotransformation
studies outlined in Chapter 4 for DZ and FLU to COC, FENT, and other drugs of abuse
and forensic importance.

132

Chapter 6: Research Summary, Implications, and Future
Works
6.1.0 Summary of Research
A review of previously published literature and research revealed that bacterial
species were capable of metabolizing complex chemical substances. Many of the
biotransformation applications discussed in Chapter 1 resulted in novel and interesting
applications toward agricultural and environmental contaminant reduction or elimination,
greater insight into the effectiveness of pharmaceutical compounds, and new
applications of isolated bacterial enzymes.
Some of these same bacterial species are native to the human GI tract and play
an active role in the postmortem decomposition process. These species have potential
to cause biotransformations that affect the ratios of compound-to-metabolite
concentrations within the human body. Such effects have rarely been considered or
evaluated, but they have potential to supply valuable information, especially concerning
compound identification and confirmation.
The purpose of this research was to develop methodology, investigate the effects
of GI bacteria on drugs of abuse, and to compare metabolites to those recovered in
human metabolic studies. Analytes of interest and (metabolites) were DZ (NDZ, OX,
TZ), FLU (7AM, NDES), COC (AEME, BZE, CE, EME, mHC, NC), and FENT (NFENT,
DESP). All of these compounds are scheduled drugs of abuse controlled by the DEA,
and for which there have been numerous studies revolving around human metabolism.
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The analytes and selected metabolites were also chosen based on the commercial
availability of certified reference standards.
Bacterial growth and preparation techniques were optimized and discussed in
Chapter 2, which included nutrient medium evaluation and selection, establishment and
maintenance of anaerobic conditions, preparation of frozen stock cultures, viable
bacterial enumeration, and a review of cellular lysis techniques. E. coli, B. fragilis, and
C. perfringens were selected because they are prominent species, viable under the
limited oxygen conditions found in the human GI tract and thereby capable of growth
and metabolism. RCM was chosen as the nutrient medium because it was able to
support the growth and proliferation of all three bacterial species. Anaerobic conditions
were established using an anaerobic chamber fitted with purge gases that worked with
a catalyst system to convert residual oxygen to H2O. Maintenance of these conditions
was critical in supporting bacterial growth, particularly for B. fragilis and C. perfringens,
anaerobic species whose growth and survival were inhibited in the presence of oxygen.
Preparation of a frozen stock culture for each species provided an ample supply
of bacteria for biotransformation studies, and the plate count procedure gave an
estimation of the viable bacteria in inoculated samples. The CFU/mL counts were
within the ranges of viable populations found in the human GI tract, specifically the
ileum (105 - 108) and colon (1010 - 1012) as reported by the NIH.45 Several cellular lysis
methods were evaluated, but all were dismissed to maintain the accuracy and integrity
of the optimized experimental conditions.
To investigate the effects of the selected bacterial species on DZ and FLU, an
LC-MS/MS method was developed for the detection, identification, and quantitation of
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these benzodiazepine compounds as well as their respective metabolites. The method
was fully validated to ensure analysis was performed and interpreted with reliability and
certainty. Analytes were recovered from RCM via SPE. To date, similar methods of
analysis and quantitation of drugs of abuse in a nutrient medium matrix have not been
published. Method development and validation were discussed in Chapter 3.
Validation was based on definitions and parameters established by the ICH,25, 89
SWGTOX26, and DHHS, FDA, CDER, and CVM.27 Linearity was addressed by creating
a calibration model for each of the analytes in RCM. Specificity was evaluated through
matrix and internal standard interference studies, ionization enhancement/suppression,
ME, RE, and PE. The carryover effects, accuracy, bias, precision (within-run precision),
repeatability (between-run precision), LOD, LOQ, range, dilution integrity, freeze-thaw
stability, processed sample stability, and robustness of the methods were also
assessed.
Dilution integrity was particularly important because biotransformation samples
were spiked at 1000 ng/mL, while the upper range of the method was only 500 ng/mL.
Dilutions were prepared at 1:2 and 1:5. Both sets met the requirements of maintaining
acceptable retention time, peak shape, an ion ratios as well as accuracy, bias, and
within-run and between-run precision. Processed sample stability was also important.
Analytes were incubated for 48 hours as part of the experimental application process.
In addition, samples were analyzed in large batches and with replicate analysis which
prolonged the time between introduction to the autosampler and LC-MS/MS analysis.
The processed sample stability study provided that samples would maintain stability for
at least 48 hours after extraction from RCM.
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Following validation, the method was applied to assess the specific effects of E.
coli, B. fragilis, and C. perfringens on DZ and FLU, which were discussed in Chapter 4.
Experiments explored the effects of environmental conditions on analyte blanks as well
as bacterial inoculates. Biotransformation studies explored the effects of individual
species as well as a mixed culture on the benzodiazepines compounds under anaerobic
conditions.
A series of bacterial blanks were prepared in RCM with aliquots of E. coli, B. fragilis,
C. perfringens, or a mixed culture without analytes of interest. These samples were
incubated under experimental conditions. None of the bacterial specimens produced
interferences with the target analytes that satisfied the requirements for peak shape,
retention time, ion ratios, and LOQ.
Analyte blanks were also examined. RCM spiked with either DZ or FLU was
incubated and analyzed. Mass balance data for DZ suggested it undergoes a partial,
unassisted degradation when incubated under experimental conditions. However, NDZ,
OX, nor TZ registered an increase from pre- to post-incubation concentrations. The
proposed degradation product was therefore unidentified.
RCM samples prepared for biotransformation studies were spiked with an
analyte of interest at 1000 ng/mL as well as either E. coli, B. fragilis, C. perfringens, or
mixed culture. Pre- and post-incubation aliquots were taken for analysis and the
change in concentration results were calculated.
Analysis of the effects of E. coli on DZ concentration produced an average DZ
concentration difference that was slightly greater than what was observed in DZ blank
samples. Consistent with the drug blank samples, NDZ, OX, nor TZ registered a
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increase from pre- to post-incubation concentrations. The mass balance discrepancies
between blank and biotransformation study samples indicated that there may be
additional factors contributing to the transformation of DZ when incubated with E.coli.
Similar results were seen in the B. fragilis biotransformation studies as well.
In both cases RCM samples showed the marked turbidity indicative of prominent
bacterial growth. A possible explanation for the discrepancy between DZ blank and E.
coli and B. fragilis biotransformation samples is that DZ was being converted to a
compound other than the monitored human metabolites. In this case, E. coli and B.
fragilis would have possessed a specific enzyme or combination of enzymes capable of
cleaving DZ to form alternative metabolites. It is unclear whether E.coli and B. fragilis
would have employed the same enzyme or if the DZ conversion was attributed to
species-specific enzymes. Additional experimental and literature review may offer
some guidance toward alternative metabolites.
Similar to the studies performed on E. coli and B. fragilis, there were negligible
changes in concentration detected for NDZ, OX, and TZ in samples inoculated with C.
perfringens. However, there was minimal change in DZ concentration as well. These
findings supported the theory of E. coli and B. fragilis were responsible for the
concentration discrepancies between the DZ drug blanks and their respective
biotransformation studies. The small change in DZ concentration, however, was unique
to C. perfringens incubations. All samples were prepared and incubated under the
same circumstances and a loss of DZ concentration comparable to at least that of the
drug blank samples was anticipated. Since DZ experienced minimal concentration loss,
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it is possible that introduction of C. perfringens stabilized the analyte and prevented
degradation.
The effects of the mixed culture studies resulted in post-incubation
concentrations similar to those seen in C. perfringens. This supported the supposition
that the presence of C. perfringens stabilized the analyte and prevented the proposed
degradation by E. coli and B. fragilis.
Analysis of the FLU drug blanks exhibited a decrease in concentration.
However, unlike what was observed in the DZ blank experiments, there was a
corresponding increase in concentration for the 7AM metabolite in the post-incubation
samples that accounted for some of the FLU loss. E. coli, B. fragilis, C. perfringens,
and the mixed culture were all capable of transforming FLU to 7AM to some extent.
Data was consistent with that published in experiments by Robert and Drummer16,17 in
which they studied effects of GI bacteria on three benzodiazepine compounds in blood.
They discovered that all three compounds were converted to their respective 7-amino
metabolites though the rate of conversion varied amongst the different species.
E. coli was capable of converting a portion of the FLU to 7AM between pre- and
post-incubation samples, which accounted for some of the FLU loss. However, not all of
the original FLU concentration was recovered as 7AM as seen in the mass balance of
the conversion. This could potentially be attributed to FLU being transformed into an
additional metabolite that was not monitored such as 3-hydroxyflunitrazepam. Another
possibility was that 7AM itself was being converted to metabolites 7-acetaminoflunitrazepam and/or 7-amino-nor-flunitrazepam. Structures for these three structures
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were presented in Figures 23 and 24. Further analysis would be required to determine
the presence and identity of these or other potential bacterial metabolites.
B. fragilis, C. perfringens, and the mixed culture completely transformed the preincubation FLU concentration in all samples. The majority was recovered as 7AM in the
post-incubation samples, but there was some concentration discrepancy. The
metabolites proposed above were the most likely candidates for minor metabolites, but
further analysis would be required.
An additional drugs of abuse and (metabolites) method was developed and fully
validated for COC (AEME, BZE, CE, EME, mHC, and NC) and FENT (NENT and
DESP) in RCM, the results of which were discussed in Chapter 5. It was validated in
similar fashion to the method for DZ and FLU. As with the DZ and FLU method, dilution
integrity was particularly important. Dilution integrity dictated that samples would be
diluted 1:5 prior to analysis. Processed sample stability was likewise an important
feature of the method validation. The processed sample stability study provided that
samples would maintain stability for 48 hours after extraction from RCM. This method is
awaiting application to study the effects of E. coli, B. fragilis, and C. perfringens on COC
and FENT.

6.2.0 Research Implications
The experimental results served as a pilot study and proof of concept. Though
the ability of bacterial species to transform complex chemical substances has been
previously studied, this methodology offers several distinct advantages. Much of the
previous research relied on germfree, gnobiotic, and conventional rats or excretions
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from volunteer human subjects. The presented methodology utilized bacterial species
for experimental purposes which eliminated the ethical considerations and guidelines
required for animal and human research endeavors.
The methodology was also cost-effective. Preparation of frozen stock cultures
for each bacterial species provided a theoretically endless supply of specimens for
transformation studies, which aided in keeping the materials costs to a minimum.
Extraction procedures, a narrow bore column, and low flow rate for instrumental
analysis minimized solvent consumption and hazardous waste production, which was
both cost-effective and environmentally friendly. In addition, the streamlined
experimental approach allowed for quantities of experimental variations to be performed
in unison, which conserved time.
The presented experimental methodology serves as a template for further
exploration of the effects of bacterial species on complex chemical compounds. The
principles behind experimental design and analysis can be adapted and applied to a
realm of possibilities. But perhaps the most important feature is the ability to streamline
experimental procedures.
These methods could be applied concurrently to determine bacterial species
candidates for biodegradation of agricultural and environmental contaminants, such as
pesticides, explosives, and chemical warfare agents. They can also be utilized to
isolate and repurpose native bacterial enzymes. This has seen promise in the medical
field as well as in sensors for drugs of abuse detection. The methods can likewise be
used in further studies concerning bacterial effects on pharmaceutical compounds and
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drugs of abuse. In addition to expanding the analytes of interest, the applications can
easily be expanded to include alternative bacterial species as well.
Ultimately, this methodology would be ideal to study compounds that are too
toxic or lethal for animal and human metabolic investigations. This would be particularly
useful in military explorations of exposure to incapacitation and chemical warfare
agents. In many of these instances, victims do not survive long enough for the
compound to undergo human metabolic conversions. Since bacterial species are
capable of transmigration postmortem as well as biotransformation of complex chemical
compounds, their metabolites could provide information that would be useful in agent or
compound identification.

6.3.0 Future Work
COC and FENT are of forensic importance. Future works should begin with the
application of the validated method for COC and FENT discussed in Chapter 5. These
analytes can easily be incorporated into analyte blank and biotransformation studies
described in Chapter 4. Development of the presented methodology and analysis of
results presented several other experimental opportunities that could expand upon and
contribute to this area of research.
Kinetic studies could be performed to determine the degradation rate of DZ and
FLU in the analyte blank samples discussed in Chapter 4. Proposed experimental
design could be based upon processed sample stability studies performed as a part of
method validation (Section 3.3.8), where an aliquot of analyte blank is taken at defined
time intervals over the course of the 48 hour incubation period, extracted, and analyzed
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via LC-MS/MS. The change in analyte concentration over time would provide an
estimate of the unassisted degradation of DZ and FLU under experimental conditions.
This conversion rate could also be compared to that calculated for each analyte when
incubated with E. coli, B. fragilis, C. perfringens, and mixed culture in biotransformation
studies. Kinetic studies could be conducted for COC and FENT conversions as well.
Identification of the other degradation and biotransformation products would likewise be
an important contribution to the DZ and FLU experiments.
Robertson and Drummer studied the effects of pH and temperature on the
compound-to-metabolite rate of conversion, which were discussed in Section 1.1.3.
Changes in the environmental and incubation conditions could be applied to study the
conversion rate of FLU to 7AM using the methods provided in Chapters 3 and 4 as well
as the proposed kinetic studies.16,17
The presented experimental methodology provides a template for further
exploration of the effects of bacterial species on complex chemical compounds. These
techniques can be expanded to include other drugs of abuse. Preliminary methods
have been developed for methadone (Appendix F) and methamphetamine (Appendix
G). These methods utilize the same HPLC buffer system and could be combined for
convenience, validated, and applied to the biotransformation studies. Other compounds
of interest such as pharmaceuticals, environmental contaminants, and explosives could
also be incorporated for analysis.
Table 4 lists the prevalent bacteria in the lower GI tract, all of which could be
incorporated into the methodology. Experiments could also be expanded to include
bacterial species other than those in the human GI tract. This methodology focused on
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facultative anaerobic and anaerobic species. However, experiments could be expanded
to include aerobic species as well. E.coli could be used to compare the effects of
aerobic vs. anaerobic conditions on biotransformation products and rates.
This method was applied to biotransformation studies of the benzodiazepine
analytes by GI bacteria. This method and application served as a proof of concept,
proving that this type of experimentation and methodology are capable of studying
bacterial metabolism of complex compounds. The methodology can expand to
encompass other drugs of abuse or compounds on interest as well as incorporate other
bacterial species.
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Appendix A – Calibration Curves for Diazepam, Flunitrazepam, and
Metabolites in Buffer
Diazepam

Nordiazepam
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Oxazepam

Temazepam
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Flunitrazepam

7-Aminoflunitrazepam
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N-Desmethylflunitrazepam
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Appendix B – Calibration Curves for Diazepam, Flunitrazepam, and
Metabolites in Media
Diazepam

Nordiazepam
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Oxazepam

Temazepam
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Flunitrazepam

7-Aminoflunitrazepam
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N-Desmethylflunitrazepam
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Appendix C – Optimized Precursor & Product Ions for Diazepam,
Flunitrazepam, and Metabolites
Diazepam Optimized Precursor & Product Ions
Compound
DZ

NDZ

OX

TZ

Fragmentor
107
107
107
107
112
112
112
112
112
112
112
112
107
107
107
107

CE (V)
29
25
25
45
25
25
25
37
17
9
37
36
17
5
41
33

Precursor (m/z)
285.1
285.1
285.1
285.1
271.1
271.1
271.1
271.1
287.1
287.1
287.1
287.1
301.1
301.1
301.1
301.1

Product (m/z)
193.0
154.0
222.1
91.0
140.0
208.0
165.0
91.0
241.0
268.9
104.0
162.9
255.0
282.9
177.0
193.0

Flunitrazepam Optimized Precursor & Product Ions
Compound
FLU

7AM

NDES

Fragmentor
135
135
135
135
140
140
140
140
125
125
125
125

CE (V)
21
33
49
33
25
17
29
29
21
37
33
29
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Precursor (m/z)
314.1
314.1
314.1
314.1
284.1
284.1
284.1
284.1
300.1
300.1
300.1
300.1

Product (m/z)
268.1
239.1
183.1
211.0
135.0
227.1
226.2
240.1
253.9
197.9
225.1
205.9

Appendix D – Calibration Curves for Cocaine, Fentanyl, and
Metabolites in Buffer
Cocaine

Anhydroecgonine Methyl Ester
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Benzoylecgonine

Cocaethylene
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Ecgonine Methyl Ester

m-Hydroxycocaine
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Norcocaine

Fentanyl

170

Norfentanyl

Despropionylfentanyl
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Appendix E – Optimized Precursor & Product Ions for Cocaine,
Fentanyl, and Metabolites
Cocaine Optimized Precursor & Product Ions
Compound
COC

AEME

BZE

CE

EME

mHC

NC

Fragmentor
96
96
96
96
96
96
96
96
96
96
96
96
96
96
96
96
96
96
96
96
96
96
96
96
96
96
96
96

CE
13
20
20
20
20
20
17
13
13
20
20
20
13
20
20
20
13
20
20
20
13
20
20
20
9
17
20
20

Precursor (m/z)
304.2
304.2
304.2
304.2
182.1
182.1
182.1
182.2
290.1
290.1
290.1
290.1
318.2
318.2
318.2
318.2
200.1
200.1
200.1
200.1
320.2
320.2
320.2
320.2
290.1
290.1
290.1
290.1
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Product (m/z)
182.0
82.0
105.0
150.0
118.0
91.0
122.0
150.4
168.0
104.9
82.0
150.0
196.0
82.0
150.0
108.0
182.0
82.0
150.0
108.0
182.0
82.0
150.0
120.9
168.0
136.0
108.0
68.0

Fentanyl Optimized Precursor & Product Ions
Compound Fragmentor
130
FENT
130
130
130
100
NFENT
100
100
100
100
DESP
100
100
100

CE
19
43
50
31
15
43
31
50
31
15
50
50

Precursor (m/z)
337.2
337.2
337.2
337.2
233.17
233.17
233.17
233.17
281.2
281.2
281.2
281.2
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Product (m/z)
188.0
105.0
79.0
132.0
84.0
55.1
93.9
128.6
105.0
188.0
79.0
103.0

Appendix F – Calibration Curves for Cocaine, Fentanyl, and
Metabolites in Media
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177

Norfentanyl
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Appendix G – Preliminary Method Development for Methadone
Methadone
Methadone (MetD) is a synthetic narcotic and Schedule II drug of abuse. 24 It is
used for medical purposes (Dolophinel®) in the detoxification and as a maintenance
treatment for those addicted to opiates. Methadone can be administered as a pill,
orally, or by injection, and is also referred to as Amidone, chocolate chip cookies,
fizzies, Maria, Pastora, and wafer.
Dependence is a common health effect for those who abuse the drug.
Withdrawal symptoms include anxiety, tremors, and vomiting. Overdose can lead to
repressed respiration, convulsions, coma, and death.24
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Metabolic Pathway of Methadone51,70,71,90-94 51,90,91,70,71,92,93,94, ,95,96,97

Methadone

EDDP

Methadol

Normethadol

EMDP

This research focused on specific metabolites 2-Ethylidene-1,5-Dimethyl-3,3Diphenylpyrrolidine (EDDP) and 2-Ethyl-5-Methyl-3,3-Diphenylpyroline (EMDP).
Methadone-d3 (MetD-d3) and 2-Ethylidene-1,5-Dimethyl-3,3-Diphenylpyrrolidine-d3
(EDDP-d3) were used as the internal standards.
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Standards were obtained from Cerilliant as 1mg/mL for MetD, EDDP, and EMDP
and as 100μg/mL concentration for MetD-d3 and EDDP-d3. The following table lists the
MRM transitions for methadone and metabolites found in the reference literature.
Methadone - Compounds, Metabolites, Precursor/Product Ions
Agilent’s MassHunter™ Optimizer Software was used to identify the optimal
quantifier and qualifier MRM transitions for methadone and its metabolites under the
dissertation research experimental conditions. These values can be found in the
following Table.
Methadone Optimized Precursor & Product Ions
Compound
MetD-d3
MetD

EDDP

EMDP

Fragmentor
100
100
100
100
100
100
160
160
160
160

CE (V)
15
27
15
27
50
19
31
19
35
43

Precursor (m/z)
313.2
313.2
310.2
310.2
310.2
310.2
278.2
278.2
278.2
278.2

Quantifier (m/z)
268.1
105.0
265.0
104.9
77.0
57.0
234.0
249.1
186.0
219.0

130
130
130

19
50
43

264.2
264.2
264.2

235.0
115.0
142.5
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Appendix H – Preliminary Method Development for Methadone
Methamphetamine
Methamphetamine (MetA) is a CNS stimulant and classified by the DEA as a
Schedule II drug of abuse.24 It is known as Desoxyn® when used for medicinal
purposes. Methamphetamine can be snorted, smoked, ingested, or injected. Some of
the many street names include bikers, black beauties, chalk, chicken feed, coffee,
crank, crystal, glass, go-fast, ice, quick, shards, speed, Tina, trash, and yellow barn.
Addiction is common for those who abuse the drug. Effects include anxiety,
confusion, paranoia, hallucinations. Methamphetamine use has also been associated
with aggressive and violent behavior. Health risks include elevated blood pressure,
body temperature, respiration, and heart rate, as well as anorexia, convulsions, dental
problems, and death.24
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Metabolic Pathway of Methamphetamine51,98-102

51,98,99,100,101, 102

Methamphetamine

p-Hydroxymethamphetamine

Amphetamine

4-Hydroxyamphetamine

Norephedrine

4-Hydroxynorephedrine

This research focused on specific metabolites p-hydroxymethamphetamine
(pHM) and amphetamine (AMP). Methamphetamine-D5 (MetA-d5) and amphetamined5 (AMP-d5) were used as internal standards.
Standards were obtained from Cerilliant in the 1mg/mL concentration for MetA
and AMP and in the 100μg/mL concentration for MetA-d5 and AMP-d5. The standard
for pHM was obtained from Sigma Aldrich as a 25mg sample. Agilent’s MassHunter™
Optimizer Software was used to identify the optimal quantifier and qualifier MRM
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transitions for methamphetamine and its metabolites under the dissertation research
experimental conditions. These values can be found in the following Table.
.
Methamphetamine Optimized Precursor & Product Ions
Compound
MetA

pHM

AMP

Fragmentor
100
100
100
100
100
100
100
100
100
100
100
100

CE (V)
19
50
50
23
19
43
21
23
19
39
27
15
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Precursor (m/z)
150.1
150.1
150.1
150.1
166.1
166.1
166.1
166.1
136.1
136.1
136.1
136.1

Product (m/z)
90.9
65.0
77.0
135.0
106.9
77.0
121.9
151.0
91.0
65.0
67.0
96.8

